<!doctype html><html class=no-js lang=en><head><meta charset=UTF-8><meta name=viewport content="width=device-width,initial-scale=1"><title>ç§‘ç ”æ—¥æŠ¥ 2025-11-21 - ç”Ÿä¿¡æ™®æ‹‰æ–¯</title>
<script>(function(e,t){e[t]=e[t].replace("no-js","js")})(document.documentElement,"className")</script><meta name=description content><meta property="og:url" content="https://ixxmu.github.io/posts/dailyreports/2025-11-21/"><meta property="og:site_name" content="ç”Ÿä¿¡æ™®æ‹‰æ–¯"><meta property="og:title" content="ç§‘ç ”æ—¥æŠ¥ 2025-11-21"><meta property="og:description" content="ğŸ“… Daily Report - 2025-11-21 ä»Šæ—¥ç­›é€‰å‡º 98 æ¡å†…å®¹ï¼Œæ¥è‡ª 4 ä¸ªæ¥æº"><meta property="og:locale" content="zh_cn"><meta property="og:type" content="article"><meta property="article:section" content="posts"><meta property="article:published_time" content="2025-11-21T00:00:00+00:00"><meta property="article:modified_time" content="2025-11-21T00:00:00+00:00"><meta property="article:tag" content="Research"><meta property="article:tag" content="Daily"><meta property="article:tag" content="Week472025"><meta itemprop=name content="ç§‘ç ”æ—¥æŠ¥ 2025-11-21"><meta itemprop=description content="ğŸ“… Daily Report - 2025-11-21 ä»Šæ—¥ç­›é€‰å‡º 98 æ¡å†…å®¹ï¼Œæ¥è‡ª 4 ä¸ªæ¥æº"><meta itemprop=datePublished content="2025-11-21T00:00:00+00:00"><meta itemprop=dateModified content="2025-11-21T00:00:00+00:00"><meta itemprop=wordCount content="2938"><meta itemprop=keywords content="Research,Daily,Week472025"><meta name=twitter:card content="summary"><meta name=twitter:title content="ç§‘ç ”æ—¥æŠ¥ 2025-11-21"><meta name=twitter:description content="ğŸ“… Daily Report - 2025-11-21 ä»Šæ—¥ç­›é€‰å‡º 98 æ¡å†…å®¹ï¼Œæ¥è‡ª 4 ä¸ªæ¥æº"><link rel=preconnect href=https://fonts.gstatic.com crossorigin><link rel=dns-prefetch href=//fonts.googleapis.com><link rel=dns-prefetch href=//fonts.gstatic.com><link rel=stylesheet href="https://fonts.googleapis.com/css?family=Open+Sans:400,400i,700"><link rel=stylesheet href=../../../css/style.css><link rel=stylesheet href=../../../css/custom.css><link rel="shortcut icon" href=../../../favicon.ico></head><body class=body><div class="container container--outer"><header class=header><div class="container header__container"><div class=logo><a class=logo__link href=../../../ title=ç”Ÿä¿¡æ™®æ‹‰æ–¯ rel=home><div class="logo__item logo__text"><div class=logo__title>ç”Ÿä¿¡æ™®æ‹‰æ–¯</div><div class=logo__tagline>è¿‘åå¹´æœ€å€¼å¾—ä¸Šæ‰‹çš„ç”Ÿç‰©åŒ»å­¦ç”Ÿä¿¡ä»£ç </div></div></a></div><nav class=menu><button class=menu__btn aria-haspopup=true aria-expanded=false tabindex=0>
<span class=menu__btn-title tabindex=-1>Menu</span></button><ul class=menu__list><li class=menu__item><a class=menu__link href=../../../posts/><span class=menu__text>æ–‡ç« </span></a></li><li class=menu__item><a class=menu__link href=../../../tags/><span class=menu__text>æ ‡ç­¾</span></a></li><li class=menu__item><a class=menu__link href=../../../about/><span class=menu__text>å…³äº</span></a></li></ul></nav></div></header><div class="wrapper flex"><div class=primary><main class=main role=main><article class=post><header class=post__header><meta name=referrer content="never"><h1 class=post__title>ç§‘ç ”æ—¥æŠ¥ 2025-11-21</h1><div class="post__meta meta"><div class="meta__item-datetime meta__item"><svg class="meta__icon icon icon-time" width="16" height="14" viewBox="0 0 30 28"><path d="M15 0a14 14 0 110 28 1 1 0 010-28m0 3a3 3 0 100 22 3 3 0 000-22m1 4h-2v8.4l6.8 4.4L22 18l-6-3.8z"/></svg><time class=meta__text datetime=2025-11-21T00:00:00Z>2025-11-21</time></div><div class="meta__item-categories meta__item"><svg class="meta__icon icon icon-category" width="16" height="16" viewBox="0 0 16 16"><path d="m7 2 1 2h8v11H0V2z"/></svg><span class=meta__text><a class=meta__link href=../../../categories/dailyreport/ rel=category>DailyReport</a></span></div><div class="meta__item-author meta__item"><svg class="meta__icon icon icon-author" width="16" height="16" viewBox="0 0 16 16"><path d="M8 1c2 0 3.5 2 3.5 4.5S10 9 10 9c3 1 4 2 4 6H2c0-4 1-5 4-6 0 0-1.5-1-1.5-3.5S6 1 8 1"/></svg><span class=meta__text>Bloger</span></div></div></header><div class="post__toc toc"><div class=toc__title>Page content</div><div class=toc__menu><nav id=TableOfContents><ul><li><a href=#-ä»Šæ—¥aiæ™ºèƒ½æ€»ç»“>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</a><ul><li><a href=#-å…¬ä¼—å·>ğŸ“° å…¬ä¼—å·</a></li><li><a href=#-æ•°æ®å‰æ²¿>ğŸ§¬ æ•°æ®å‰æ²¿</a></li><li><a href=#-æœŸåˆŠæ–‡ç« >ğŸ”¬ æœŸåˆŠæ–‡ç« </a></li><li><a href=#-åšå®¢æ›´æ–°>ğŸ§ª åšå®¢æ›´æ–°</a></li></ul></li><li><a href=#-åˆ†ç±»æµè§ˆ>ğŸ“š åˆ†ç±»æµè§ˆ</a><ul><li></li></ul></li><li><a href=#-å…³é”®è¯ç»Ÿè®¡>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</a></li><li><a href=#-æ›´å¤šå†…å®¹>ğŸ“ æ›´å¤šå†…å®¹</a></li></ul></nav></div></div><div class="content post__content clearfix"><h1 id=-daily-report---2025-11-21>ğŸ“… Daily Report - 2025-11-21</h1><blockquote><p>ä»Šæ—¥ç­›é€‰å‡º <strong>98</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>4</strong> ä¸ªæ¥æº</p></blockquote><div class=powered-by-top>Powered by <a href=https://kyplus.de>ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href=https://claude.ai>Claude</a></div><hr><h2 id=-ä»Šæ—¥aiæ™ºèƒ½æ€»ç»“>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2><h3 id=-å…¬ä¼—å·>ğŸ“° å…¬ä¼—å·</h3><blockquote><p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š
Natureé¦–æ¬¡æ­ç¤ºæŸ“è‰²è´¨è°ƒèŠ‚å› å­SATB1è°ƒæ§Tç»†èƒï¼Œä¸ºç™Œç—‡å…ç–«æ²»ç–—å¼€è¾Ÿæ–°é€”å¾„ï¼›CellæŠ€æœ¯çªç ´STAMPå®ç°ç™¾ä¸‡å•ç»†èƒåˆ†æã€‚</p></blockquote><p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š</p><ul><li><strong>è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒç ”ç©¶</strong>ï¼šå•ç»†èƒåˆ†æè¯†åˆ«HLA-DR+è‚¿ç˜¤ç»†èƒã€PLAUR+ä¸­æ€§ç²’ç»†èƒã€MMP11+æˆçº¤ç»´ç»†èƒï¼ŒåŠå…¶å¯¹Tç»†èƒå’Œå…ç–«æ²»ç–—æ•ˆæœçš„å½±å“ï¼›ç©ºé—´è½¬å½•ç»„å­¦æ­ç¤ºä¾µè¢­æ€§å‰åˆ—è…ºç™Œå¾®ç¯å¢ƒç‰¹å¾ã€‚</li><li><strong>å…ç–«æ²»ç–—æ–°æœºåˆ¶æ¢ç´¢</strong>ï¼šCD47â€œåˆ«åƒæˆ‘â€ä¿¡å·åˆ†å­ä¿ƒè¿›Tç»†èƒè€—ç«­ï¼›CAF-ç™Œç»†èƒé€šè®¯ä»‹å¯¼PARPiè€è¯ã€‚</li><li><strong>ç¥ç»å…ç–«ä¸ç–¾ç—…æœºåˆ¶</strong>ï¼šèƒ¶è´¨ç˜¤ç¥ç»å…ç–«é€ƒé€¸æ–°æœºåˆ¶ï¼›ç™«ç—«å‘ç—…å‰è¡€æµ†è›‹ç™½è´¨å˜åŒ–è§„å¾‹ã€‚</li></ul><p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š</p><ul><li><strong>ç©ºé—´ç»„å­¦æŠ€æœ¯</strong>ï¼šVisium HDã€Stereo-seq V2ï¼ˆFFPEåˆ‡ç‰‡å•ç»†èƒç²¾åº¦å…¨è½¬å½•ç»„å®šä½ï¼‰ç­‰å¹³å°æ€§èƒ½æµ‹è¯„ã€‚</li><li><strong>å•ç»†èƒæ•°æ®å¤„ç†</strong>ï¼šPythonå¤„ç†ç–‘éš¾æ‚ç—‡æ•°æ®ã€RåŒ…å¤„ç†GEOæ•°æ®ã€‚</li></ul><h3 id=-æ•°æ®å‰æ²¿>ğŸ§¬ æ•°æ®å‰æ²¿</h3><blockquote><p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š
è‚¿ç˜¤å…ç–«ç–—æ³•æ–°ç­–ç•¥ï¼šåˆ©ç”¨é¶å‘è‚¿ç˜¤ç›¸å…³å·¨å™¬ç»†èƒçš„å…ç–«ç»†èƒå› å­ï¼ŒååŒTç»†èƒå’ŒNKç»†èƒå¢å¼ºæŠ—ç™Œæ•ˆæœã€‚</p></blockquote><p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š</p><ul><li>è‚¿ç˜¤å…ç–«ï¼šç ”ç©¶è‚¿ç˜¤ç›¸å…³å·¨å™¬ç»†èƒã€NKç»†èƒã€Tç»†èƒåœ¨ç™Œç—‡å…ç–«ä¸­çš„ä½œç”¨åŠè°ƒæ§æœºåˆ¶ã€‚</li><li>ç»†èƒä»£è°¢ä¸è¯ç‰©æŠµæŠ—ï¼šæ¢ç´¢DDX6ç›¸åˆ†ç¦»è°ƒæ§AMLä»£è°¢å¯å¡‘æ€§å’Œè€è¯æ€§ã€‚</li><li>ç¥ç»é€€è¡Œæ€§ç–¾ç—…å…ç–«ï¼šç ”ç©¶Tç»†èƒåœ¨äº¨å»·é¡¿ç—…ç¥ç»é€€è¡Œä¸­çš„ç‰©ç§ç‰¹å¼‚æ€§å…ç–«æµ¸æ¶¦ã€‚</li></ul><p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š</p><ul><li>CITE-seqå’Œå•ç»†èƒRNAæµ‹åºï¼ˆscRNA-seqï¼‰æŠ€æœ¯åœ¨è‚¿ç˜¤å…ç–«å’Œç–¾ç—…ç ”ç©¶ä¸­çš„åº”ç”¨ã€‚</li><li>CRISPRç­›é€‰æŠ€æœ¯ç”¨äºè§£æAMLè¯ç‰©æŠµæŠ—æœºåˆ¶ã€‚</li></ul><h3 id=-æœŸåˆŠæ–‡ç« >ğŸ”¬ æœŸåˆŠæ–‡ç« </h3><blockquote><p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š
æ–°å‹å…ç–«ç»†èƒå› å­ä¸é¶å‘æŠ—ä½“è”åˆæ²»ç–—æ™šæœŸå®ä½“è‚¿ç˜¤å±•ç°æ½œåŠ›ï¼›FaceAgeä½œä¸ºç”Ÿç‰©æ ‡å¿—ç‰©åœ¨å¤§å‹è‚¿ç˜¤é˜Ÿåˆ—ä¸­ç”¨äºé¢„åå’Œæ²»ç–—åˆ†å±‚ã€‚</p></blockquote><p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š</p><ul><li>è¯„ä¼°Cergutuzumab amunaleukinè”åˆé˜¿æ›¿ä½åˆ©ç å•æŠ—æ²»ç–—æ™šæœŸCEAé˜³æ€§å®ä½“è‚¿ç˜¤çš„å®‰å…¨æ€§ä¸æ´»æ€§ã€‚</li><li>æ¢ç´¢åŸå‘æ€§ç¡¬åŒ–æ€§èƒ†ç®¡ç‚ç›¸å…³èƒ†é“ç™Œçš„ä¸´åºŠåŸºå› ç»„å­¦ç‰¹å¾åŠæ²»ç–—ç­–ç•¥ã€‚</li><li>åˆ†æèƒ°è…ºç™Œä¸­é›Œæ¿€ç´ ç”Ÿæˆå¯¹è‚¿ç˜¤å¾®ç¯å¢ƒçš„å½±å“æœºåˆ¶ã€‚</li><li>è¯„ä¼°FaceAgeï¼ˆåŸºäºé¢éƒ¨ç…§ç‰‡çš„ç”Ÿç‰©å¹´é¾„ä¼°ç®—ç³»ç»Ÿï¼‰ä½œä¸ºè‚¿ç˜¤é¢„åå’Œæ²»ç–—åˆ†å±‚çš„ç”Ÿç‰©æ ‡å¿—ç‰©ã€‚</li></ul><p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š</p><ul><li>è”åˆä½¿ç”¨å…ç–«ç»†èƒå› å­ï¼ˆIL-2å˜å¼‚ä½“ï¼‰ä¸é¶å‘æŠ—ä½“ï¼ˆCergutuzumab amunaleukinï¼‰ã€‚</li><li>åˆ©ç”¨æ·±åº¦å­¦ä¹ ç³»ç»ŸFaceAgeä¼°ç®—ç”Ÿç‰©å¹´é¾„ï¼Œé¢„æµ‹ç”Ÿå­˜ç‡å’Œæ—©æœŸæ­»äº¡ç‡ã€‚</li></ul><h3 id=-åšå®¢æ›´æ–°>ğŸ§ª åšå®¢æ›´æ–°</h3><blockquote><p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š
æ–°å‹åˆ†å­åœ¨é˜¿å°”èŒ¨æµ·é»˜ç—…æ¨¡å‹ä¸­æ˜¾è‘—é€†è½¬ç—…ç—‡ï¼›ç§‘å­¦å®¶æˆåŠŸé‡å¡‘å…ç–«ç»†èƒï¼Œæ˜¾è‘—å¢å¼ºæŠ—ç™Œèƒ½åŠ›ã€‚</p></blockquote><p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š</p><ul><li>ç™Œç—‡å…ç–«ç–—æ³•ï¼šé€šè¿‡é‡å¡‘Tç»†èƒåŠŸèƒ½ï¼Œå…‹æœè‚¿ç˜¤å…ç–«æŠ‘åˆ¶ï¼Œæå‡æ²»ç–—æ•ˆæœã€‚</li><li>ç¥ç»é€€è¡Œæ€§ç–¾ç—…ï¼šå¼€å‘é¶å‘Î²-æ·€ç±³æ ·è›‹ç™½æ–‘å—çš„æ–°å‹å°åˆ†å­ï¼Œåœ¨åŠ¨ç‰©æ¨¡å‹ä¸­å±•ç°è®°å¿†æ¢å¤å’Œç‚ç—‡ç¼“è§£ã€‚</li><li>ç»„ç»‡å†ç”Ÿï¼šæ­ç¤ºè‚Œè‚‰å¹²ç»†èƒå¦‚ä½•é€šè¿‡RNAè°ƒæ§å¼•å¯¼å·¨å™¬ç»†èƒï¼Œé©±åŠ¨è¾èˆå°¾éƒ¨å†ç”Ÿã€‚</li><li>ç½•è§ç—…è¯Šæ–­ï¼šåˆ©ç”¨RNAæµ‹åºæŠ€æœ¯ï¼Œè¯†åˆ«DNAæ£€æµ‹é—æ¼çš„åŸºå› è¡¨è¾¾å¼‚å¸¸ï¼Œæé«˜ç½•è§ç—…è¯Šæ–­å‡†ç¡®æ€§ã€‚</li><li>éª¨é«“å¾®ç¯å¢ƒä¸ç–¾ç—…ï¼šé˜æ˜æ…¢æ€§ç‚ç—‡å¦‚ä½•é‡å¡‘éª¨é«“ï¼Œä¿ƒè¿›çªå˜å¹²ç»†èƒå…‹éš†å¢æ®–ï¼Œä¸ç–¾ç—…å‘ç”Ÿç›¸å…³ã€‚</li><li>è‚¾è„ç–¾ç—…æ²»ç–—ï¼šç ”å‘æ–°å‹æŠ—ä½“ï¼Œé¶å‘å¤šå›Šè‚¾è„ç–¾ç—…çš„å…³é”®ä¿¡å·é€šè·¯ï¼Œåœ¨åŠ¨ç‰©ç ”ç©¶ä¸­æ˜¾ç¤ºå‡ºå‡ç¼“æˆ–é€†è½¬ç—…æƒ…çš„æ½œåŠ›ã€‚</li></ul><p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š</p><ul><li><strong>RNAæµ‹åº</strong>ï¼šå®ç°å¯¹FFPEæ ·æœ¬çš„å…¨è½¬å½•ç»„å•ç»†èƒåˆ†æï¼Œæ‹“å±•äº†åŸºå› è¡¨è¾¾ç ”ç©¶çš„æ ·æœ¬ç±»å‹å’Œåˆ†è¾¨ç‡ã€‚</li><li><strong>æ–°å‹æŠ—ä½“å·¥ç¨‹</strong>ï¼šè®¾è®¡èƒ½å¤Ÿæ¸—é€è‚¾è„å›Šè‚¿å¹¶é˜»æ–­ç‰¹å®šç”Ÿé•¿ä¿¡å·çš„æŠ—ä½“ã€‚</li></ul><hr><h2 id=-åˆ†ç±»æµè§ˆ>ğŸ“š åˆ†ç±»æµè§ˆ</h2><details><summary style="text-align:right;direction:rtl;padding:10px 15px;background:linear-gradient(135deg,#f8f9fa 0%,#e9ecef 100%);border-right:4px solid #667eea;font-weight:600;cursor:pointer;margin:15px 0;border-radius:6px">ğŸ“° å…¬ä¼—å· (38æ¡)</summary><div class=details-content markdown=1><h4 id=è¯¦ç»†å†…å®¹å‰10æ¡>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4><p><strong>1.</strong> â­ <strong>æœ€æ–°14+ç”Ÿä¿¡ï¼Œé€šè¿‡å•ç»†èƒåˆ†æè¯†åˆ«HLA-DR +è‚¿ç˜¤ç»†èƒï¼Œå¹¶åˆ†æå…¶å¯¹ CD8+T ç»†èƒåŠé¢„åçš„å½±å“ï¼Œæ€è·¯æ–°é¢–ï¼</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€Tç»†èƒã€å•ç»†èƒã€ç”Ÿä¿¡ã€é€šè·¯</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503989&amp;idx=7&amp;sn=c83766b30c9d2ebf79d51526dd63b27e">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>2.</strong> â­ <strong>æœ€æ–°10+ç”Ÿä¿¡ï¼Œéå¸¸åŠ¡å®çš„æ–‡ç« ã€‚è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒä¸­å…³é”®å…ç–«ç”Ÿç‰©æ ‡å¿—ç‰©çš„æ³›ç™Œç©ºé—´ç‰¹å¾åˆ†æ</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€å…ç–«ã€å…ç–«å¾®ç¯å¢ƒã€å¾®ç”Ÿç‰©ã€ç”Ÿä¿¡</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503989&amp;idx=1&amp;sn=dc81d8f1a2a2a43ece30c6a89d7de64c">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>3.</strong> â­ <strong>æœ€æ–°14+ç”Ÿä¿¡ï¼Œå•ç»†èƒè¯†åˆ«PLAUR+ä¸­æ€§ç²’ç»†èƒå¡‘é€ å…ç–«æŠ‘åˆ¶å¾®ç¯å¢ƒï¼ŒæŠ‘åˆ¶PLAUR å¢å¼ºæŠ— PD1 ç–—æ•ˆã€‚é«˜åˆ†æ–‡ç« ç»å…¸æ€è·¯ï¼</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€å…ç–«å¾®ç¯å¢ƒã€å•ç»†èƒã€ç”Ÿä¿¡</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503989&amp;idx=5&amp;sn=6438b279898eb358c7e00a6e072200d5">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>4.</strong> â­ <strong>Natureé¦–æ¬¡æ­ç¤ºæŸ“è‰²è´¨è°ƒèŠ‚å› å­ï¼šSATB1è°ƒæ§Tç»†èƒï¼Œä¸ºç™Œç—‡å…ç–«æ²»ç–—å¼€æ–°æŒ‚ï¼</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡äºº</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡ã€å…ç–«ã€Tç»†èƒã€Bç»†èƒ</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šåœ¨æ…¢æ€§ç—…æ¯’æ„ŸæŸ“å’Œç™Œç—‡ä¸­ï¼ŒCD8+ Tç»†èƒé•¿æœŸæš´éœ²äºæŠ—åŸåˆºæ¿€ä¸‹ä¼šé€æ¸åˆ†åŒ–ä¸ºè¡°ç«­Tç»†èƒï¼Œå…¶ç‰¹å¾æ˜¯åŠŸèƒ½å—æŸã€æŠ‘åˆ¶æ€§å—</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248646&amp;idx=1&amp;sn=5eb6a4142fdb2daa4594d018f4ca7f2a">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>5.</strong> â­ <strong>å•èƒå¯å¡‘ | Nature | èµ·æºåŸºåº•ç»†èƒè§£æç™Œç—‡ä¸­ç¥ç»å†…åˆ†æ³Œ-ç°‡çŠ¶ç»†èƒè°±ç³»å¯å¡‘æ€§</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šBioJournal Link</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡ã€Tç»†èƒã€ç¥ç»ã€å•ç»†èƒ</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg5NjgxNjkwOA==&amp;mid=2247503137&amp;idx=1&amp;sn=c960e9fb56d2c0fd571831cd71be5b44">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>6.</strong> â­ <strong>10.6åˆ†éè‚¿ç˜¤å¹²æ¹¿ç»“åˆç”Ÿä¿¡ï¼Œé¶å‘ CD177 + ä¸­æ€§ç²’ç»†èƒå‡è½»ç¼ºè¡€å†çŒæ³¨æŸä¼¤ã€‚é€‚åˆåŠ¨ç‰©å»ºæ¨¡æµ‹åºæ€è·¯ï¼</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€æµ‹åºã€ç”Ÿä¿¡</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503989&amp;idx=6&amp;sn=02d6d73bb12a3f637bee6f58d2c9d151">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>7.</strong> â­ <strong>è·Ÿç€æ–‡çŒ®å­¦ä¹ VisiumHDå•ç»†èƒç©ºé—´è½¬å½•ç»„æ•°æ®å¤„ç†ï¼Œè¿™ä¸ªå¤§å®¶åšçš„ä¹Ÿè¶Šæ¥ä¹Ÿå¤šäº†</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡é’±åŒå­¦</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå•ç»†èƒã€ç©ºé—´è½¬å½•ç»„ã€è½¬å½•ç»„</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šå¥½çš„ç©ºé—´ç»„å­¦ä»£ç å­¦ä¹ </li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzkwMzY2NjkwNg==&amp;mid=2247495626&amp;idx=1&amp;sn=9a5f3884b0e1e8cea40d7336e507dc04">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>8.</strong> â­ <strong>ã€Šè‡ªç„¶Â·å…ç–«å­¦ã€‹ï¼šåº·å¥ˆå°”å›¢é˜Ÿé¦–æ¬¡å‘ç°ï¼Œâ€œåˆ«åƒæˆ‘â€ä¿¡å·åˆ†å­CD47ï¼Œç«Ÿç„¶è¿˜èƒ½ä¿ƒè¿›Tç»†èƒè€—ç«­ï¼Œå‰Šå¼±æŠ—è‚¿ç˜¤å…ç–«ï¼</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šå¥‡ç‚¹è‚¿ç˜¤æ¢ç§˜</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€å…ç–«ã€Tç»†èƒ</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šä¸€æ¡è°ƒæ§Tç»†èƒè€—ç«­çš„æ–°é€šè·¯ç°èº«ï¼Œä¸ºæ”¹å–„å…ç–«æ²»ç–—æ•ˆæœæä¾›äº†æ–°çš„æ¢ç´¢æ–¹å‘ã€‚</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzI4ODc5MDI5NA==&amp;mid=2247503527&amp;idx=1&amp;sn=eaf3a923eb3e9dd36ebef58f18067652">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>9.</strong> â­ <strong>Cancer Cell+1ï¼é™†å†›å†›åŒ»å¤§æ­ç¤ºèƒ¶è´¨ç˜¤çš„ç¥ç»å…ç–«é€ƒé€¸æ–°æœºåˆ¶ï¼</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šä»Šæ—¥ç—…ç†</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€å…ç–«ã€ç¥ç»</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzU1OTkyMTE4Mg==&amp;mid=2247488952&amp;idx=1&amp;sn=9e873f78c9df24641f9d2df54cff79aa">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>10.</strong> â­ <strong>æ–‡çŒ®åˆ†äº«&ndash;ç©ºé—´å¤šç»„å­¦æŠ€æœ¯æ­ç¤ºä¾µè¢­æ€§å‰åˆ—è…ºç™Œç‰¹å¾ï¼šè‚¿ç˜¤å¾®ç¯å¢ƒä¸­ä¿ƒç‚æ€§è¶‹åŒ–å› å­æ´»æ€§çš„å…³é”®ä½œç”¨</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šå•ç»†èƒç©ºé—´äº¤å“ä¹</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€è¶‹åŒ–å› å­ã€ç©ºé—´ç»„å­¦</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šæ–‡çŒ®åˆ†äº«&ndash;ç©ºé—´å¤šç»„å­¦æŠ€æœ¯æ­ç¤ºä¾µè¢­æ€§å‰åˆ—è…ºç™Œç‰¹å¾ï¼šè‚¿ç˜¤å¾®ç¯å¢ƒä¸­ä¿ƒç‚æ€§è¶‹åŒ–å› å­æ´»æ€§çš„å…³é”®ä½œç”¨</li><li>ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg2MDY1NTYyOQ==&amp;mid=2247499033&amp;idx=1&amp;sn=b96466d84df856b7b36d7592a72809d5">æŸ¥çœ‹åŸæ–‡</a></li></ul><blockquote><p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 28 æ¡å†…å®¹ï¼Œè¯¦è§ <a href=#%E6%9B%B4%E5%A4%9A-%E5%85%AC%E4%BC%97%E5%8F%B7>æ–‡æœ«</a></p></blockquote></div></details><details><summary style="text-align:right;direction:rtl;padding:10px 15px;background:linear-gradient(135deg,#f8f9fa 0%,#e9ecef 100%);border-right:4px solid #667eea;font-weight:600;cursor:pointer;margin:15px 0;border-radius:6px">ğŸ§¬ æ•°æ®å‰æ²¿ (45æ¡)</summary><div class=details-content markdown=1><h4 id=è¯¦ç»†å†…å®¹å‰10æ¡-1>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4><p><strong>1.</strong> â­ <strong>GSE302715 ä¸€ç§è‚¿ç˜¤ç›¸å…³å·¨å™¬ç»†èƒé¶å‘å…ç–«ç»†èƒå› å­ï¼Œåˆ©ç”¨ T ç»†èƒå’Œ NK ç»†èƒçš„ååŒä½œç”¨è¿›è¡Œå¼ºæ•ˆç™Œç—‡å…ç–«æ²»ç–— [scRNA-seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€macrophageã€NK cellã€regex:immuno(logy|therapy|suppression)ã€scRNA</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Michelle von Locquenghien ; Pascale Zwicky ; Ken Xie ; Diego Jaitin ; Fadi Sheban ; Florian Uhlitz ; Chamutal Gur ; Reut Sharet Eshed ; Eyal David ; Kfir Mazuz ; Jahan Adeeb Rahman ; Noam Solomon ; Roberto Avellino ; Assaf Weiner ; Ido AmitSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusTumor-associated macrophages (TAMs) expressing the myeloid checkpoint TREM2 are key immunosuppressive cells in the tumor microenvironment (TME), driving tumor progression and contributing to poor prognosis in cancer patients. Due to their pivotal role, TAMs have emerged as a promising target for immunotherapies. However, current TAM-targeting monotherapies show only modest efficacy in clinical trials in solid tumors . Here, we have developed a new class of cancer immunotherapies: myeloid-targeted immunocytokines and NK-T cell enhancers (MiTEs). MiTEs are trans-acting immunocytokines with tumor-specific activation, allowing dual targeting of TAMs and lymphocytes by TREM2 antagonism and cytotoxic effector cell activation through IL-2. To avoid off-target toxicities, MiTEs contain an IL-2 masking moiety, which is cleaved by a TAM-specific protease. MiTEs demonstrate high efficacy in preclinical tumor models through extensive immune reprogramming spanning TAM, T and NK cell compartments. MiTEs show transformative potential for treating solid-cancers by inducing potent multi-arm anti-tumor immunity and minimizing toxicities.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302715">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>2.</strong> â­ <strong>GSE303870 ä¸€ç§é¶å‘è‚¿ç˜¤ç›¸å…³å·¨å™¬ç»†èƒçš„å…ç–«ç»†èƒå› å­ï¼Œåˆ©ç”¨Tç»†èƒå’ŒNKç»†èƒçš„ååŒä½œç”¨ï¼Œå®ç°å¼ºæ•ˆçš„ç™Œç—‡å…ç–«æ²»ç–—</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€macrophageã€NK cellã€regex:immuno(logy|therapy|suppression)</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencing ; OtherOrganism : Homo sapiens ; Mus musculusThis SuperSeries is composed of the SubSeries listed below.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303870">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>3.</strong> â­ <strong>GSE303868 ä¸€ç§è‚¿ç˜¤ç›¸å…³å·¨å™¬ç»†èƒé¶å‘å…ç–«ç»†èƒå› å­ï¼Œåˆ©ç”¨ T ç»†èƒå’Œ NK ç»†èƒçš„ååŒä½œç”¨è¿›è¡Œå¼ºæ•ˆç™Œç—‡å…ç–«æ²»ç–— [CITE-seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€macrophageã€NK cellã€regex:immuno(logy|therapy|suppression)</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Michelle von Locquenghien ; Pascale Zwicky ; Ken Xie ; Diego Jaitin ; Fadi Sheban ; Florian Uhlitz ; Chamutal Gur ; Reut Sharet Eshed ; Eyal David ; Kfir Mazuz ; Jahan Adeeb Rahman ; Noam Solomon ; Roberto Avellino ; Assaf Weiner ; Ido AmitSeries Type : Expression profiling by high throughput sequencing ; OtherOrganism : Homo sapiensTumor-associated macrophages (TAMs) expressing the myeloid checkpoint TREM2 are key immunosuppressive cells in the tumor microenvironment (TME), driving tumor progression and contributing to poor prognosis in cancer patients. Due to their pivotal role, TAMs have emerged as a promising target for immunotherapies. However, current TAM-targeting monotherapies show limited efficacy, highlighting the need for strategies engaging multiple immune modalities. Here, we developed a new class of cancer immunotherapies: myeloid-targeted immunocytokines and NK-T cell enhancers (MiTEs). MiTEs are trans-acting immunocytokines with tumor-specific activation, allowing dual targeting of TAMs and lymphocytes by TREM2 antagonism and cytotoxic effector cell activation through IL-2. To avoid off-target toxicities, MiTEs contain an IL-2 masking moiety, which is cleaved by a TAM-specific protease. MiTEs demonstrate high efficacy in preclinical tumor models through extensive immune reprogramming spanning TAM, T and NK cell compartments. MiTEs show transformative potential for treating solid-cancers by inducing potent multi-arm anti-tumor immunity and minimizing toxicities.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303868">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>4.</strong> â­ <strong>GSE281973 è‚¿ç˜¤æµ¸æ¶¦æ€§ NK ç»†èƒ (tuNK) ä¸è„¾è„ NK ç»†èƒ (spNK) çš„åŠŸèƒ½å’Œè½¬å½•è°±æ¯”è¾ƒ [RNA-seq]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€NK cellã€RNA-seq</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Yi Wang ; Li Tang ; Yugang GuoSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusNatural killer (NK) cells, a type of potent cytotoxic lymphocytes, are particularly promising for the treatment of cancers that lose or downregulate major histocompatibility complex class I (MHC-I) expression to evade T cell-mediated immunotherapy. However, the hostile and immune suppressive tumor microenvironment (TME) greatly hinders the function of tumor-infiltrating NK cells limiting the therapeutic efficacy against solid tumors. Here, we show that a fusion protein of interleukin-21 (IL-21âˆ’Fc), as a direct in vivo intervention, can safely and effectively reprogram NK cell metabolism and enhance their effector function in the TME. Our research demonstrates that combining IL-21âˆ’Fc with IL-15 superagonist (IL-15SA) or NK cell transfer leads to the eradication of MHC-I-deficient tumors and confers durable protection in syngeneic and xenograft tumor models. Mechanistically, we uncover that IL-21âˆ’Fc enhances NK cell effector function by upregulating glycolysis in a lactate dehydrogenase A (LDHA)-dependent manner. These findings not only underscore the considerable potential of IL-21âˆ’Fc as an in vivo therapeutic intervention to bolster NK cell-based immunotherapy, but also unveil an innovative strategy of metabolic reprogramming for NK cell rejuvenation within tumors.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281973">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>5.</strong> â­ <strong>GSE254278 å•ç»†èƒè½¬å½•ç»„å­¦æ­ç¤ºäº¨å»·é¡¿ç—…ç¥ç»é€€è¡Œæ€§å˜ä¸­Tç»†èƒçš„ç‰©ç§ä¾èµ–æ€§å…ç–«æµ¸æ¶¦</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€single-cellã€transcriptomics</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Jiawei Li ; Yingqi Lin ; Sen YanSeries Type : Expression profiling by high throughput sequencingOrganism : Sus scrofaImmune infiltration of T cells in the brain has been observed in various pathological conditions, but whether this phenomenon occurs in Huntington disease (HD) remains unknown. To address this question, we conducted an investigation using HD knock-in pigs, which exhibit selective neurodegeneration similar to HD patients. Single-cell transcriptomes identified that glial cells are the most abundant cell type in the human and pig striatum, while neurons outnumber glial cells in the mouse striatum. HD knock-in pigs recapitulate the loss of specific types of striatal neurons (iSPN and dSPN) observed in HD patients, a phenomenon not observed in HD knock-in mice. The increased IFN-activated microglia subgroup in HD knock-in pigs was found to secrete CCL8 chemokines to recruit CD8+ T cells. These T cells release perforin and granzyme, leading to the degeneration of striatal neurons. Although HD-KI mouse striatum does not show elevated CCL8, administration of CCL8 resulted in an increase in CD8+ T cells and a reduction in neuronal cells. These findings suggest that species-dependent abundance of glial cells and the effects of mutant huntingtin on glial cells contribute to microglia-driven immune infiltration of CD8+ T cells, ultimately playing a critical role in the selective neurodegeneration in HD.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE254278">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>6.</strong> â­ <strong>GSE248419 Zeb1-Cxcl1è½´é€šè¿‡è¯±å¯¼ä¹³è…ºç™Œä¸­M2å·¨å™¬ç»†èƒæåŒ–æ¥å‰Šå¼±æŠ—è‚¿ç˜¤å…ç–«ååº” II</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€immuneã€macrophage</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusZeb1, a classic epithelial-mesenchymal transition (EMT) regulator, has recently been found to be involved in M2 macrophage polarization in the tumor immune microenvironment, thereby promoting tumor development. However, the underlying mechanism of Zeb1-induced M2 macrophage polarization remains largely unexplored. To identify the potential role of Zeb1 in remodeling the tumor immune microenvironment in breast cancer, we crossed the floxed Zeb1 allele homozygously into PyMT mice to generate PyMT;Zeb1cKO (MMTV-Cre; PyMT;Zeb1fl/fl) mice. We found that the recruitment of M2 macrophages was significantly reduced in tumors from PyMT;Zeb1cKO mice, along with weakening of the tumor suppressive effect. Mechanistically, Zeb1 plays a crucial role in transcriptionally promoting the expression of Cxcl1 in tumor cells and enhancing the secretion of Cxcl1 in serum. Eventually, Cxcl1 activated the JAK-Stat3 signature via Cxcr2 and then induced the M2 polarization of macrophages, which leads to T cell inactivation and impairs the antitumor immune response in breast cancer. Our results revealed the important role of Zeb1 in the remodeling of the breast cancer tumor microenvironment, suggesting a novel therapeutic intervention for the treatment of advanced cancers.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE248419">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>7.</strong> â­ <strong>GSE248418 Zeb1-Cxcl1è½´é€šè¿‡è¯±å¯¼ä¹³è…ºç™Œä¸­M2å·¨å™¬ç»†èƒæåŒ–æ¥æŸå®³æŠ—è‚¿ç˜¤å…ç–«ååº” I</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€immuneã€macrophage</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensZeb1, a classic epithelial-mesenchymal transition (EMT) regulator, has recently been found to be involved in M2 macrophage polarization in the tumor immune microenvironment, thereby promoting tumor development. However, the underlying mechanism of Zeb1-induced M2 macrophage polarization remains largely unexplored. To identify the potential role of Zeb1 in remodeling the tumor immune microenvironment in breast cancer, we crossed the floxed Zeb1 allele homozygously into PyMT mice to generate PyMT;Zeb1cKO (MMTV-Cre; PyMT;Zeb1fl/fl) mice. We found that the recruitment of M2 macrophages was significantly reduced in tumors from PyMT;Zeb1cKO mice, along with weakening of the tumor suppressive effect. Mechanistically, Zeb1 plays a crucial role in transcriptionally promoting the expression of Cxcl1 in tumor cells and enhancing the secretion of Cxcl1 in serum. Eventually, Cxcl1 activated the JAK-Stat3 signature via Cxcr2 and then induced the M2 polarization of macrophages, which leads to T cell inactivation and impairs the antitumor immune response in breast cancer. Our results revealed the important role of Zeb1 in the remodeling of the breast cancer tumor microenvironment, suggesting a novel therapeutic intervention for the treatment of advanced cancers.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE248418">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>8.</strong> <strong>GSE310106 DDX6 å‘ç”Ÿç›¸åˆ†ç¦»ä»¥è°ƒèŠ‚ AML ä¸­çš„ä»£è°¢å¯å¡‘æ€§å’Œè€è¯æ€§ [CRISPR ç­›é€‰]</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šmetabolicã€resistance</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Rui Su ; Chun-Wei (David) Chen ; Hongjie Bi ; Anthony ChanSeries Type : OtherOrganism : Homo sapiensChemoresistance in acute myeloid leukemia (AML) is a major cause of poor prognosis and frequent relapse among patients. Under stress conditions such as chemotherapy or radiotherapy, processing bodies (PBs) and stress granules (SGs) can sequester essential mRNAs and proteins to modulate leukemia cell survival. However, the precise role(s) of PBs and SGs in AML pathogenesis and chemotherapy response remains unclear. To systematically identify PB/SG-associated genes that are critical for AML survival, we selected 101 genes encoding RNA-binding proteins that are localized within PBs and SGs, and constructed a customized CRISPR library targeting these genes for both in vitro and in vivo CRISPR screening with AML cell line (Mono-Mac-6) and patient-derived xenograft (PDX) cells.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310106">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>9.</strong> <strong>GSE304762 åˆ©ç”¨åŸºå› æ¡å½¢ç å’Œå•ç»†èƒè½¬å½•ç»„å­¦è§£æé£Ÿç®¡ç™Œå‰ç—…å˜ä¸­å‰ä½“ç»†èƒçš„åŠ¨æ€å˜åŒ–</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsingle-cellã€transcriptomics</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : OtherOrganism : Mus musculusEsophageal preneoplastic cells, despite appearing histologically normal, exhibit early genetic alterations and lineage plasticity, yet their origins and trajectories remain unclear. This study employs genetic barcoding combined with single-cell RNA sequencing to trace the lineage of esophageal preneoplastic cells and identify a distinct progenitor-like population with high plasticity. Through a newly developed scoring system, high-plasticity cells are mapped, revealing their contributions to proliferative and basal cell populations. The study identifies key molecular markers, including Nfib and Qk, that define these precursor cells. These findings provide critical insights into early tumorigenesis, highlighting the potential of precursor cells as biomarkers for early cancer detection and therapeutic targeting. By elucidating the cellular dynamics underlying esophageal cancer initiation, this research lays the foundation for strategies to prevent malignant progression, offering broader implications for improving cancer diagnostics and treatment approaches.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304762">æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>10.</strong> <strong>GSE291689 Pfkfb1 é€‰æ‹©æ€§åœ°è¯†åˆ«å«æœ‰èƒå†…ç”Ÿé•¿ç»†èŒçš„å·¨å™¬ç»†èƒ</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šbacteriaã€regex:bacter(ia|ial|ium)</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Li Fan ; Yang SunSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThrough releasing virulence molecules into host cells, intracellular bacteria interfere with host cellular functions and grow in the cells that engulf them. To ensure survival and virulence, these pathogens also manipulate host factors, but this process is not fully understood. In this study, we investigated the host molecular mechanisms required for intracellular bacterial growth in macrophages using Salmonella typhimurium (Salmonella) infection model and bacterial division reporter system. Upon Salmonella infection, Protein Phosphatase 6 (Pp6) was significantly reduced in macrophages containing growing bacteria. Conditional knockout of Pp6 increased host susceptibility to Salmonella-mediated killing, which was attributed to the poor resistance in Pp6-deficient macrophages. MicroRNA-31 (miR-31) was identified as a negative regulator of Pp6, and its conditional deletion promoted Salmonella clearance. Moreover, a yeast two-hybrid screening identified 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 (Pfkfb1), a key metabolic regulator, as a substrate of Pp6. Pp6-deficient macrophages exhibited elevated Pfkfb1 expression. Furthermore, we found that macrophages containing growing Salmonella exclusively exhibited high Pfkfb1 expression. Pfkfb1 deletion reduced bacterial growth, likely due to increased NO levels, while also downregulating arginase-1 (Arg-1) expression and impairing arginine biosynthesis and metabolism in macrophages. Together, we investigated the role of Pp6-Pfkfb1 axis in orchestrating host metabolic adaptions and intracellular bacterial survival, which may provide therapeutic targets for infectious diseases against intracellular multidrug-resistant bacteria.</li><li>ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291689">æŸ¥çœ‹åŸæ–‡</a></li></ul><blockquote><p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 35 æ¡å†…å®¹ï¼Œè¯¦è§ <a href=#%E6%9B%B4%E5%A4%9A-%E6%95%B0%E6%8D%AE%E5%89%8D%E6%B2%BF>æ–‡æœ«</a></p></blockquote></div></details><details><summary style="text-align:right;direction:rtl;padding:10px 15px;background:linear-gradient(135deg,#f8f9fa 0%,#e9ecef 100%);border-right:4px solid #667eea;font-weight:600;cursor:pointer;margin:15px 0;border-radius:6px">ğŸ”¬ æœŸåˆŠæ–‡ç«  (8æ¡)</summary><div class=details-content markdown=1><h4 id=è¯¦ç»†å†…å®¹å…¨éƒ¨8æ¡>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨8æ¡ï¼‰</h4><p><strong>1.</strong> <strong>Cergutuzumab Amunaleukin ä¸é˜¿æ›¿ä½åˆ©ç å•æŠ—è”åˆæ²»ç–—ç™Œèƒšé˜³æ€§æ™šæœŸ/è½¬ç§»æ€§å®ä½“è‚¿ç˜¤æ‚£è€…</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€æŠ—ä½“</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ç›®çš„ï¼šCergutuzumab amunaleukinï¼ˆCAï¼‰æ˜¯ä¸€ç§å…ç–«ç»†èƒå› å­ï¼Œç”±ç™½ä»‹ç´ -2 å˜å¼‚å½¢å¼ç»„æˆï¼ˆè®¾è®¡ä¸ºé¿å… CD25 ç»“åˆå’Œ Treg åˆºæ¿€ï¼‰ï¼Œèåˆäºè‡´ç™ŒèƒšèƒæŠ—åŸï¼ˆCEAï¼‰é¶å‘æŠ—ä½“ã€‚è¯¥ Ib æœŸå¼€æ”¾æ ‡ç­¾ã€å¤šä¸­å¿ƒå‰‚é‡é€’å¢ä¸æ‰©å±•ç ”ç©¶ï¼ˆNCT02350673ï¼‰è¯„ä¼°äº† CA åŠ é˜¿æ›¿å”‘ç å•æŠ—åœ¨æ™šæœŸ/è½¬ç§»æ€§ CEA é˜³æ€§å®ä½“è‚¿ç˜¤æ‚£è€…çš„å®‰å…¨æ€§ã€æ´»æ€§ã€è¯ä»£åŠ¨åŠ›å­¦å’Œè¯æ•ˆå­¦ã€‚æ‚£è€…ä¸æ–¹æ³•ï¼šæ‚£è€…æ¯ 2 å‘¨ï¼ˆæ¯ 2 å‘¨ï¼‰æ¥å— CA å‰‚é‡é€’å¢ï¼ˆ6â€“20/25 æ¯«å…‹ï¼‰ä¸å›ºå®šå‰‚é‡é˜¿æ›¿å”‘ç å•æŠ—ï¼ˆ840 æ¯«å…‹ï¼‰;æˆ–æ¯å‘¨é€’å¢å‰‚é‡ CAï¼ˆ10â€“15/20 æ¯«å…‹ï¼‰ä¸å›ºå®šå‰‚é‡é˜¿æ›¿å”‘ç å•æŠ—ï¼ˆ1200 æ¯«å…‹ï¼‰æ¯ 3 å‘¨ï¼ˆæ¯ 3 å‘¨ï¼‰é€’å¢å‰‚é‡ã€‚ä¸»è¦ç›®æ ‡ï¼šæœ€å¤§è€å—å‰‚é‡ï¼ˆMTDï¼‰;æ‰©å¼ æ¨èå‰‚é‡ï¼ˆRDEï¼‰;å®‰å…¨ã€‚ç»“æœï¼š24 åæ‚£è€…è¢«éšæœºåˆ†é…ä¸ºæ¯ 2 å‘¨æ¥å— CA åŠ é˜¿æ›¿å”‘ç å•æŠ—ï¼Œ45 åæ‚£è€…ä¸º CA QW åŠ é˜¿æ›¿å”‘ç å•æŠ—æ¯ 3 å‘¨</li><li>ğŸ”— <a href=https://m.x-mol.com/paper/1991257205251354624/t>æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>2.</strong> <strong>å¤å‘/éš¾æ²»æ€§å¤§ B ç»†èƒæ·‹å·´ç˜¤æ‚£è€… JULIET è¯•éªŒäº”å¹´åˆ†æ</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šæ·‹å·´ã€Bç»†èƒ</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ä¸´åºŠè‚¿ç˜¤å­¦æ‚å¿—ï¼Œå°åˆ·å‰ã€‚</li><li>ğŸ”— <a href=https://m.x-mol.com/paper/1991257298360709120/t>æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>3.</strong> <strong>åŸå‘æ€§ç¡¬åŒ–æ€§èƒ†ç®¡ç‚ç›¸å…³èƒ†é“ç™Œçš„ä¸´åºŠåŸºå› ç»„å­¦ç‰¹å¾</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šåŸºå› ç»„</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ç›®çš„ï¼šèƒ†é“ç™Œï¼ˆBTCï¼‰æ˜¯åŸå‘æ€§ç¡¬åŒ–æ€§èƒ†ç®¡ç‚ï¼ˆPSCï¼‰æ‚£è€…çš„ä¸»è¦æ­»å› ã€‚ä¸ PSC ç›¸å…³çš„ BTC ç›®å‰å°šä¸å……åˆ†ï¼Œå¸¸è§„å’Œå…ç–«ç–—æ³•çš„é£é™©ä¸ç›Šå¤„å°šä¸æ˜ç¡®ã€‚æˆ‘ä»¬çš„ç›®æ ‡æ˜¯è¡¨å¾ PSC ç›¸å…³ BTCs çš„ä¸´åºŠç»“å±€å’ŒåŸºå› ç»„ã€‚å®éªŒè®¾è®¡ï¼šè¿™æ˜¯ä¸€é¡¹å›é¡¾æ€§é˜Ÿåˆ—ç ”ç©¶ï¼Œé’ˆå¯¹åœ¨ MD Anderson ç™Œç—‡ä¸­å¿ƒï¼ˆN=46ï¼‰å’Œç›æ ¼ä¸½ç‰¹å…¬ä¸»ç™Œç—‡ä¸­å¿ƒï¼ˆN=16ï¼‰æ¥å—æ²»ç–—çš„åŸºç¡€ PSC æ‚£è€…çš„ BTC æ‚£è€…ï¼Œä¸é PSC ç›¸å…³ BTC æ‚£è€…ï¼ˆN=146ï¼‰è¿›è¡Œäº†å¯¹æ¯”ã€‚æˆ‘ä»¬æ¯”è¾ƒäº† PSC ä¸é PSC çš„ç»“å±€ï¼Œä»¥åŠæœ‰æ— å…ç–«æ²»ç–—çš„ PSC æ²»ç–—ã€‚é¶å‘æµ‹åºï¼ˆN=139ï¼‰ã€å…¨åŸºå› ç»„æµ‹åºï¼ˆN=27ï¼‰åŠå…¨åŸºå› ç»„é…å¯¹ RNA æµ‹åºï¼ˆN=33ï¼‰çš„ç»„åˆï¼Œæç»˜äº† PSC ç›¸å…³ BTCs çš„åŸºå› ç»„å’Œè½¬å½•ç»„æ ¼å±€ã€‚ç»“æœï¼šåœ¨ PSC ç›¸å…³ BTC ä¸­ï¼Œå°†å…ç–«æ²»ç–—åŠ å…¥åŒ–ç–—ä¸æ”¹å–„ä¸€çº¿æ— è¿›å±•ç”Ÿå­˜æœŸç›¸å…³ï¼ˆN=22 å¯¹ 11ï¼Œä¸­ä½ PFS 12.2 å¯¹ 4.7 ä¸ªæœˆï¼‰ï¼Œ</li><li>ğŸ”— <a href=https://m.x-mol.com/paper/1991257199857479680/t>æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>4.</strong> <strong>éšç€åŒç‰¹å¼‚æ€§æŠ—ä½“ä¸Šå‡ï¼Œåˆ©å¦¥æ˜”å•æŠ—/å‰è¥¿ä»–æ»¨/å¥¥æ²™åˆ©é“‚çš„ä½¿ç”¨æ—¥è½ï¼šSUNMO è¯•éªŒ</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šæŠ—ä½“</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ä¸´åºŠè‚¿ç˜¤å­¦æ‚å¿—ï¼Œå°åˆ·å‰ã€‚</li><li>ğŸ”— <a href=https://m.x-mol.com/paper/1990916707953258496/t>æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>5.</strong> <strong>èƒ°è…ºç™Œä¸­çš„é›Œæ¿€ç´ ç”Ÿæˆå¡‘é€ äº†æŠ‘åˆ¶è‚¿ç˜¤çš„åŸºè´¨å¾®ç¯å¢ƒ</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ç”±äºç¼ºä¹æœ‰æ•ˆçš„æ²»ç–—å¹²é¢„ï¼Œèƒ°ç®¡è…ºç™Œï¼ˆPDACï¼‰æ˜¯å¯¼è‡´ç™Œç—‡ç›¸å…³æ­»äº¡çš„ä¸»è¦åŸå› ä¹‹ä¸€ã€‚PDAC è‚¿ç˜¤é«˜åº¦çº¤ç»´åŒ–ï¼Œé—´è´¨ä¸°åº¦è¢«å‡è®¾å¯¹æ‚£è€…ç»“å±€æœ‰å½±å“ã€‚ç„¶è€Œï¼ŒåŸºè´¨æˆçº¤ç»´ç»†èƒå¯èƒ½ä¿ƒè¿›è‚¿ç˜¤å¹¶æŠ‘åˆ¶è‚¿ç˜¤ï¼Œè¿™æˆ–è®¸èƒ½è§£é‡ŠåŸºè´¨é¶å‘æ²»ç–—ä»¤äººå¤±æœ›çš„ä¸´åºŠç»“æœã€‚æˆ‘ä»¬è§‚å¯Ÿåˆ°ï¼Œå¥³æ€§ PDAC æ‚£è€…çš„è¡€æ¸…é—´è´¨ç”Ÿç‰©æ ‡å¿—ç‰©æ°´å¹³æ˜¾è‘—é«˜äºç”·æ€§æ‚£è€…ã€‚è¿™ä¸€è§‚ç‚¹å¾—åˆ°äº†å¯¹å®ä½“ç™Œé—´è´¨ä¸°åº¦çš„è®¡ç®—æœºä¼°è®¡ï¼Œä»¥åŠç£å…±æŒ¯å¼¹æ€§æˆåƒå’Œç»„ç»‡æŸ“è‰²çš„æ”¯æŒï¼Œè¿™äº›æ–¹æ³•æ˜¾ç¤ºå¥³æ€§ PDAC æ‚£è€…çš„è‚¿ç˜¤ç»„ç»‡æ›´ä¸ºåšç¡¬ã€‚åŸºå› è¡¨è¾¾åˆ†ææ˜¾ç¤ºï¼Œé›Œæ¿€ç´ ä¿¡å·ä¼ å¯¼æŒ‡ç¤ºä¸€ä¸ªåŸºè´¨æˆçº¤ç»´æ¯ç»†èƒè¡¨å‹ï¼Œè¯¥è¡¨å‹ä¸ç›¸å¯¹æƒ°æ€§åˆ†å­äºšå‹ç›¸å…³ï¼Œä¸”é¢„åæ›´ä¸ºè‰¯å¥½ï¼Œè€Œè¯¥é¢„åç”± C å‹å‡é›†ç´  CLEC3B çš„åŸºè´¨è¡¨è¾¾ç»´æŒã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œé›Œæ¿€ç´ åœ¨è‚¿ç˜¤å†…è¢«æ£€æµ‹åˆ°ï¼Œèƒ°è…ºç™Œç»†èƒè¡¨è¾¾äº†ä¿ƒæˆé›Œæ¿€ç´ åˆæˆçš„å…³é”®é…¶ã€‚PDAC ä¸­çš„é›Œæ¿€ç´ äº§ç”Ÿç”±åŸºè´¨è¡ç”Ÿçš„åˆ†æ”¯é“¾æ°¨åŸºé…¸åˆ†è§£ä½œç”¨æ¨åŠ¨ï¼Œæœ€ç»ˆäº§ç”Ÿç±»å›ºé†‡æ¿€ç´ å‰ä½“ã€‚è¿™äº›æ•°æ®å…±åŒæ­ç¤ºäº†é‡è¦çš„æ¿€ç´ é©±åŠ¨å› ç´ ï¼Œé€šè¿‡é‡ç¼–ç¨‹è‚¿ç˜¤å¾®ç¯å¢ƒæ¥é™åˆ¶è‚¿ç˜¤è¿›å±•ï¼Œå¹¶ä¸º</li><li>ğŸ”— <a href=https://m.x-mol.com/paper/1991264624819941376/t>æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>6.</strong> <strong>åŠ æ‹¿å¤§é’å°‘å¹´å’Œé’å¹´ç™Œç—‡åè·¨æ€§åˆ«å’Œå¹´é¾„çš„æ”¶å…¥ã€‚</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: èƒŒæ™¯ é’å°‘å¹´å’Œå¹´è½»æˆäººï¼ˆAYAsï¼‰ç™Œç—‡åœ¨å…³é”®çš„è¿‡æ¸¡é˜¶æ®µå‡ºç°ï¼Œå¯¹è´¢åŠ¡å¥åº·äº§ç”ŸæŒä¹…å½±å“ã€‚ç›®å‰å°šä¸ç¡®å®š AYAs ä¸­çš„ç™Œç—‡æ˜¯å¦ä¼šå› æ€§åˆ«å’Œè¯Šæ–­å¹´é¾„éšæ—¶é—´åœ¨æ”¶å…¥ä¸Šè¡¨ç°å‡ºå·®å¼‚ã€‚æ–¹æ³• æˆ‘ä»¬å°†åŠ æ‹¿å¤§å›½å®¶ç™Œç—‡ç™»è®°å¤„ä¸ä¸ªäººç¨åŠ¡è®°å½•å…³è”ï¼Œä»¥è¯†åˆ« 1994 å¹´è‡³ 2013 å¹´é—´è¯Šæ–­çš„ AYAï¼ˆ15-39 å²ï¼‰ã€‚åœ¨ç¡®è¯Šå‰ä¸€å¹´ï¼Œå¹¸å­˜è€…åœ¨å¤šä¸ªç¤¾ä¼šäººå£å­¦ç‰¹å¾ä¸Šä¸ 10 åæ— ç™Œè€…è¿›è¡Œäº†å˜å¼‚æ¯”åŒ¹é…ã€‚å‚ä¸è€…çš„çºµå‘éšè®¿æ—¶é—´æœ€é•¿å¯è¿½æº¯è‡³è¯Šæ–­å 10 å¹´æˆ– 2015 å¹´ã€‚ä½¿ç”¨åŒç¨³å¥å·®åˆ†ä¼°ç®—ç›¸å¯¹å’Œç»å¯¹æ”¶å…¥å˜åŒ–ã€‚æˆ‘ä»¬å°†å¹´é¾„åˆ†ä¸ºä¸‰ç»„ï¼šé’å°‘å¹´ï¼ˆ15-17 å²ï¼‰ã€æ–°å…´é’å¹´ï¼ˆ18-29 å²ï¼‰å’Œé’å¹´æˆäººï¼ˆ30-39 å²ï¼‰ï¼Œåæ˜ äº†ä¸åŒçš„ AYA ç”Ÿå‘½é˜¶æ®µã€‚åˆ†ææŒ‰æ€§åˆ«å’Œè¯Šæ–­å¹´é¾„åˆ†å±‚ã€‚ç»“æœï¼šå¥³æ€§å¹¸å­˜è€… 60,240 äººï¼Œç”·æ€§å¹¸å­˜è€… 33,085 äººï¼Œåˆ†åˆ«åŒ¹é…åˆ°æ— ç™Œè€… 490,645 äººå’Œ 274,595 äººã€‚æ€»ä½“è€Œè¨€ï¼Œç”·æ€§å’Œå¥³æ€§æ”¶å…¥å‡å°‘ç‡åˆ†åˆ«ä¸º 6.9%ï¼ˆ95%ç½®ä¿¡åŒºé—´ï¼š5</li><li>ğŸ”— <a href=https://m.x-mol.com/paper/1991265111577309184/t>æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>7.</strong> <strong>FaceAge ä½œä¸ºå¤§å‹è‚¿ç˜¤å­¦é˜Ÿåˆ—é¢„åå’Œæ²»ç–—åˆ†å±‚çš„ç”Ÿç‰©æ ‡å¿—ç‰©ã€‚</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: èƒŒæ™¯ï¼šäººç±»è¡°è€é€Ÿåº¦ä¸åŒï¼Œé¢éƒ¨ç‰¹å¾å¯èƒ½æ­ç¤ºç”Ÿç‰©å¹´é¾„å’Œç”Ÿç†å¥åº·çŠ¶å†µã€‚FaceAge æ˜¯ä¸€æ¬¾é€šè¿‡é¢éƒ¨ç…§ç‰‡ä¼°ç®—ç”Ÿç‰©å¹´é¾„çš„æ·±åº¦å­¦ä¹ ç³»ç»Ÿï¼Œå·²å±•ç°å‡ºä½œä¸ºç™Œç—‡é¢„åç”Ÿç‰©æ ‡å¿—ç‰©çš„æ½œåŠ›ã€‚æœ¬ç ”ç©¶æ¢è®¨äº†é¢éƒ¨å¹´é¾„ä¸å®é™…å¹´é¾„ï¼ˆFaceAge-Ageï¼‰ä¹‹é—´æç«¯ä¸ä¸€è‡´åœ¨é¢„æµ‹ç”Ÿå­˜ç‡å’Œæ—©æœŸæ­»äº¡ç‡ä¸­ï¼Œæ¶µç›– 28 ç§ç™Œç—‡ç±»å‹çš„å¤§å‹ä¸´åºŠæ•°æ®é›†ä¸­çš„é¢„åä»·å€¼ã€‚æ–¹æ³•ï¼šåˆ†æäº† 2008 å¹´è‡³ 2023 å¹´é—´æ¥å—æ”¾ç–—çš„ 24,556 åå¹´é¾„â‰¥60 å²çš„ç™Œç—‡æ‚£è€…çš„æ•°æ®ã€‚åœ¨ä¸åŒè¯Šæ–­/ä¸´åºŠèƒŒæ™¯ä¸‹ï¼Œæ¯”è¾ƒäº† FaceAge ä¼°è®¡å€¼ä¸æ—¶é—´å¹´é¾„ï¼Œå¹¶è¿›è¡Œäº†ç”Ÿå­˜åˆ†æã€‚æ‰€æœ‰æµ‹è¯•å‡ä¸ºåŒé¢æµ‹è¯•ã€‚ç»“æœ FaceAge åœ¨ 65%çš„å¹´é¾„ä¸­æ¯”å®é™…å¹´é¾„æ›´è€ï¼ˆä¸­ä½æ•°ä¸º 74 å²å¯¹ 70 å²ï¼‰ã€‚å¹´è½»æ‚£è€…ã€å¥³æ€§ã€é¢„åè¾ƒå·®ä¸”æ¥å—ç¼“å’Œæ„å›¾æ²»ç–—çš„æ‚£è€…ï¼Œè„¸é¾„-å¹´é¾„â‰¥10 å²çš„å¯èƒ½æ€§æ›´é«˜ã€‚é¢å¹´é¾„å¹´é¾„â‰¥10 å²æ‚£è€…å­˜æ´»ç‡æ˜¾è‘—è¾ƒä½ï¼Œè€Œé¢å¹´é¾„å¹´é¾„â‰¤-5 å²æ‚£è€…å­˜æ´»ç‡è¾ƒä½³ã€‚åœ¨å¤šå˜é‡åˆ†æä¸­ï¼ŒFaceAge-Ageâ‰¥10</li><li>ğŸ”— <a href=https://m.x-mol.com/paper/1991265117394808832/t>æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>8.</strong> <strong>è‚¿ç˜¤ç›¸å…³ç”Ÿç‰©ç±»ä¼¼è¯çš„é‡‡ç”¨ï¼šå…¨çƒä½¿ç”¨æ•°æ®åˆ†æã€‚</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: èƒŒæ™¯ç”Ÿç‰©åˆ¶å‰‚æå¤§åœ°æ”¹å–„äº†ç™Œç—‡ç®¡ç†ï¼Œä½†æˆæœ¬è¾ƒé«˜ã€‚ç”Ÿç‰©ç±»ä¼¼è¯æˆæœ¬è¾ƒä½ï¼Œä¸”ä¸å‚è€ƒäº§å“ç›¸æ¯”æ²¡æœ‰ä¸´åºŠæ„ä¹‰ä¸Šçš„å·®å¼‚ã€‚ç„¶è€Œï¼Œå®ƒä»¬å¹¶ä¸å®Œå…¨ç›¸åŒï¼Œå¯¼è‡´ä¸´åºŠåŒ»ç”Ÿå’Œæ‚£è€…å¯¹ä½¿ç”¨å®ƒä»¬æŒçŠ¹è±«æ€åº¦ã€‚ç›®çš„ æµ‹é‡ç¾å›½åŠç±»ä¼¼ç›‘ç®¡æ¡†æ¶å›½å®¶ä¸­è‚¿ç˜¤ç›¸å…³ç”Ÿç‰©ç±»ä¼¼è¯ç›¸è¾ƒäºå‚è€ƒäº§å“çš„é‡‡ç”¨æƒ…å†µã€‚æ–¹æ³• æˆ‘ä»¬äº 2022 å¹´ 10 æœˆè‡³ 2023 å¹´ 9 æœˆæœŸé—´ï¼Œåœ¨ 13 ä¸ªå›½å®¶å¯¹äº”ç§å«ç”Ÿç‰©ç±»ä¼¼è¯çš„è‚¿ç˜¤ç›¸å…³ç”Ÿç‰©åˆ¶å‰‚è¿›è¡Œäº†æ¨ªæ–­é¢é”€å”®åˆ†æï¼šè´ä¼ç å•æŠ—ã€è²æ ¼æ‹‰æ–¯æ±€ã€å‘éæ ¼æ‹‰æ–¯æ±€ã€åˆ©å¦¥æ˜”å•æŠ—å’Œæ›²å¦¥ç å•æŠ—ã€‚æˆ‘ä»¬ä½¿ç”¨äº† IQVIA MIDASÂ®å…³äºå›½å®¶å±‚é¢å­£åº¦é”€å”®é‡å’Œä»·å€¼çš„æ•°æ®ã€‚ç»“æœ åœ¨ 13 ä¸ªå›½å®¶ä¸­ï¼Œç¾å›½åœ¨è‚¿ç˜¤ç›¸å…³ç”Ÿç‰©ç±»ä¼¼è¯çš„é‡‡ç”¨æ¯”ä¾‹ï¼ˆæŒ‰é”€å”®å•ä½è®¡ 75%å¯¹ä¸­ä½æ•° 86%ï¼‰å’Œæ”¯å‡ºæ¯”ä¾‹ï¼ˆ58%å¯¹ 76%ï¼‰æ–¹é¢æ’åç¬¬åã€‚ç¾å›½ç”Ÿç‰©ç±»ä¼¼è¯çš„é‡‡ç”¨ç‡ä¸ºï¼šéæ ¼ç‘å¸æ±€ 84%ï¼ˆå¯¹æ¯” 95%ï¼‰ï¼Œè´ä¼å•æŠ— 83%ï¼ˆå¯¹æ¯” 86%ï¼‰ï¼Œåˆ©å¦¥æ˜”å•æŠ— 75%ï¼ˆå¯¹æ¯” 93%ï¼‰ï¼Œæ›²å¦¥ç å•æŠ—</li><li>ğŸ”— <a href=https://m.x-mol.com/paper/1991265127071068160/t>æŸ¥çœ‹åŸæ–‡</a></li></ul></div></details><details><summary style="text-align:right;direction:rtl;padding:10px 15px;background:linear-gradient(135deg,#f8f9fa 0%,#e9ecef 100%);border-right:4px solid #667eea;font-weight:600;cursor:pointer;margin:15px 0;border-radius:6px">ğŸ§ª åšå®¢æ›´æ–° (7æ¡)</summary><div class=details-content markdown=1><h4 id=è¯¦ç»†å†…å®¹å…¨éƒ¨7æ¡>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨7æ¡ï¼‰</h4><p><strong>1.</strong> <strong>ç§‘å­¦å®¶é‡æ–°æ¿€æ´»ç–²æƒ«çš„Tç»†èƒï¼Œä»¥å¢å¼ºç™Œç—‡å…ç–«åŠ›ã€‚</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€immunity</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šResearchers discovered a way to keep T cells from wearing out during the fight against cancer, and the approach could make immune-based treatments far more powerful. They found that tumors use a particular molecular signal to weaken T cells, and that interrupting this signal helps the cells stay active.</li><li>ğŸ”— <a href=https://www.sciencedaily.com/releases/2025/11/251120002828.htm>æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>2.</strong> <strong>RNAæµ‹åºæ­ç¤ºäº†è‚Œè‚‰å¹²ç»†èƒå¦‚ä½•å¼•å¯¼å·¨å™¬ç»†èƒä¿ƒè¿›èŒèšªå°¾éƒ¨å†ç”Ÿã€‚</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencing</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šRNA sequencing reveals how muscle stem cells use c1qtnf3 to shift macrophages toward regeneration, enabling African clawed frog tadpoles to regrow functional tails&mldr;</li><li>ğŸ”— <a href=https://www.rna-seqblog.com/rna-sequencing-reveals-how-muscle-stem-cells-guide-macrophages-to-drive-tadpole-tail-regeneration/>æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>3.</strong> <strong>RNAæµ‹åºä¸ºä»¥å¾€æ— æ³•ç¡®è¯Šçš„ç½•è§ç—…ç—…ä¾‹æä¾›äº†åŠŸèƒ½æ€§è§è§£å’Œè¯Šæ–­ä¾æ®ã€‚</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencing</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šRNA sequencing uncovers hidden splicing and regulatory defects, improving diagnostic clarity for rare disease cases when DNA tests fall short.</li><li>ğŸ”— <a href=https://www.rna-seqblog.com/rna-sequencing-provides-functional-insights-and-diagnostic-resolution-in-previously-unsolved-rare-disease-cases/>æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>4.</strong> <strong>Parse Bioscienceså…¬å¸å®£å¸ƒæ¨å‡ºä¸FFPEå…¼å®¹çš„æ¡å½¢ç æŠ€æœ¯ï¼Œç”¨äºå…¨è½¬å½•ç»„å•ç»†èƒåˆ†æã€‚</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štranscriptome</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šRNA sequencing of FFPE tissues gains whole transcriptome, single cell resolution through&mldr;</li><li>ğŸ”— <a href=https://www.rna-seqblog.com/parse-biosciences-announces-ffpe-compatible-barcoding-technology-for-whole-transcriptome-single-cell-analysis/>æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>5.</strong> <strong>ä¸€ç§ç®€å•çš„åˆ†å­åœ¨è€é¼ èº«ä¸Šå±•ç°å‡ºæ˜¾è‘—çš„é˜¿å°”èŒ¨æµ·é»˜ç—…é€†è½¬ä½œç”¨</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šAlzheimer</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šScientists have developed a new molecule that breaks down beta-amyloid plaques by binding to excess copper in the brain. The treatment restored memory and reduced inflammation in rats, while also proving non-toxic and able to cross the bloodâ€“brain barrier. Because itâ€™s far simpler and potentially cheaper than existing drugs, researchers are now pursuing partnerships to begin human trials.</li><li>ğŸ”— <a href=https://www.sciencedaily.com/releases/2025/11/251118220052.htm>æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>6.</strong> <strong>ç‚ç—‡ä½¿éª¨é«“æˆä¸ºç–¾ç—…æ»‹ç”Ÿçš„æ¸©åºŠã€‚</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šinflammation</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šResearchers discovered that chronic inflammation fundamentally remodels the bone marrow, allowing mutated stem cell clones to quietly gain dominance with age. Reprogrammed stromal cells and interferon-responsive T cells create a self-sustaining inflammatory loop that weakens blood production. Surprisingly, the mutant cells themselves may not be the main instigators.</li><li>ğŸ”— <a href=https://www.sciencedaily.com/releases/2025/11/251118220049.htm>æŸ¥çœ‹åŸæ–‡</a></li></ul><p><strong>7.</strong> <strong>æŠ—ä½“æ–°çªç ´æˆ–å°†æœ€ç»ˆå‡ç¼“å¤šå›Šè‚¾ç—…çš„å‘å±•</strong></p><ul><li>âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…</li><li>ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šantibody</li><li>ğŸ“ <strong>æè¿°</strong>ï¼šA specially engineered antibody that can infiltrate kidney cysts has shown the ability to block key growth signals driving polycystic kidney disease. Early mouse studies suggest it may halt or even reverse cyst expansion without harming healthy tissue.</li><li>ğŸ”— <a href=https://www.sciencedaily.com/releases/2025/11/251118220046.htm>æŸ¥çœ‹åŸæ–‡</a></li></ul></div></details><h2 id=-å…³é”®è¯ç»Ÿè®¡>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2><table><thead><tr><th>å…³é”®è¯</th><th>å‡ºç°æ¬¡æ•°</th></tr></thead><tbody><tr><td>ç”Ÿä¿¡</td><td>11</td></tr><tr><td>è‚¿ç˜¤</td><td>11</td></tr><tr><td>å…ç–«</td><td>8</td></tr><tr><td>Tç»†èƒ</td><td>8</td></tr><tr><td>cancer</td><td>8</td></tr><tr><td>epigenome</td><td>8</td></tr><tr><td>å•ç»†èƒ</td><td>7</td></tr><tr><td>tumor</td><td>5</td></tr><tr><td>macrophage</td><td>5</td></tr><tr><td>ç¥ç»</td><td>5</td></tr><tr><td>sequencing</td><td>4</td></tr><tr><td>NK cell</td><td>4</td></tr><tr><td>RNA-seq</td><td>4</td></tr><tr><td>immune</td><td>4</td></tr><tr><td>é€šè·¯</td><td>3</td></tr><tr><td>inflammation</td><td>3</td></tr><tr><td>regex:immuno(logy</td><td>therapy</td></tr><tr><td>æŠ—ä½“</td><td>3</td></tr><tr><td>ç™Œç—‡</td><td>3</td></tr><tr><td>single-cell</td><td>3</td></tr></tbody></table><hr><h2 id=-æ›´å¤šå†…å®¹>ğŸ“ æ›´å¤šå†…å®¹</h2><details><summary><a name=æ›´å¤š-å…¬ä¼—å·></a>ğŸ“° å…¬ä¼—å· å…¶ä»–å†…å®¹ (28æ¡)</summary><div class=details-content markdown=1><ul><li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2OTU2MzM2NA==&amp;mid=2247493027&amp;idx=1&amp;sn=fe2aa45924eb23bcf06e5034464f968e">æœ€æ–°8åˆ†ç”Ÿä¿¡ï¼Œç©ºè½¬å¤šç»„å­¦åˆ†ææ­ç¤ºCAF-ç™Œç»†èƒé€šè®¯ä»‹å¯¼ PARPi è€è¯çš„å…¨æ–°æœºåˆ¶ï¼Œå†…å®¹å¾ˆå°‘ï¼Œä¼˜åŠ¿åœ¨äºè‡ªæµ‹æ•°æ®</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503989&amp;idx=4&amp;sn=3212c3dc84df1bdff5591f883548d08d">åˆšåˆšå‘è¡¨çš„8.9åˆ†ç”Ÿä¿¡ï¼Œé™¤äº†è¯†åˆ«æŸåŸºå› é˜³æ€§ç»†èƒï¼Œè¯†åˆ«æŸé€šè·¯/è¡¨å‹é˜³æ€§ç»†èƒä¹Ÿæ˜¯å‘æ–‡çš„å¥½æ€è·¯ï¼</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503989&amp;idx=3&amp;sn=8851b792a937b9cf3935b78a328b47fc">33+ç”Ÿä¿¡ï¼Œ è¯†åˆ«ä»ç™Œå‰ç—…å˜åˆ°è‚¿ç˜¤ä¸åŒæ¶æ€§ç¨‹åº¦ç›¸å…³çš„ç»†èƒäºšå‹ï¼Œé’ˆå¯¹IL-33+å†…çš®ç»†èƒä¿ƒè¿›ç–¾ç—…è¿›å±•è¿›è¡Œå®éªŒéªŒè¯ï¼</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2NDcxMzYwNg==&amp;mid=2247490875&amp;idx=1&amp;sn=f8d0ae48f05b2a069eb2421d47431995">ç©ºé—´è½¬å½•ç»„å¹³å°æ€ä¹ˆé€‰ï¼ŸåŒ—å¤§å›¢é˜Ÿ5å¤§å¹³å°ç³»ç»Ÿæ€§æµ‹è¯„Visium HDã€Stereo-seq ã€CosMx 6Kã€Xenium 5K</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzAxMDkxODM1Ng==&amp;mid=2247547083&amp;idx=1&amp;sn=4c15c623ab9c3ae5e59dc34b5f7068e4">ä½¿ç”¨pythonè¯»å–ç–‘éš¾æ‚ç—‡çš„å•ç»†èƒæ•°æ®ï¼ˆGSM7870858ï¼‰</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzU0ODQyNjQxOA==&amp;mid=2247555117&amp;idx=1&amp;sn=236d239fabd95df1c48953be166e40f2">Cell ï½œ åå¤§åŸºå› ï¼šStereo-seq V2ä»¥å•ç»†èƒç²¾åº¦é‡å¡‘FFPEç©ºé—´å…¨è½¬å½•å®‡å®™</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248646&amp;idx=4&amp;sn=6f4cb14277329070821137d0cd9fb90f">CellæŠ€æœ¯çªç ´ï¼ŒSTAMPè®©ç™¾ä¸‡å•ç»†èƒåˆ†æä¸æ˜¯é—®é¢˜!</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2NDcxMzYwNg==&amp;mid=2247490954&amp;idx=1&amp;sn=118acfee15aedb9c440d4064d629b94b">Natureæœ€æ–°ï¼å¯’é—¨å¥³åšå£«è§£å†³å›½å®¶ç”Ÿç‰©ä¿¡æ¯å­¦é¢†åŸŸ50å¹´â€œå¡è„–å­â€æŠ€æœ¯ï¼å‰é€”æ— é‡ï¼</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&amp;mid=2656510323&amp;idx=3&amp;sn=a2b9fb0e12b4953421db47693b4c99c1">å¤§è§„æ¨¡è¡€æµ†è›‹ç™½è´¨ç»„å­¦åˆ†æï¼éƒé‡‘æ³°&è°­å…°å›¢é˜Ÿé¦–æ¬¡ç³»ç»Ÿæ€§æ­ç¤ºç™«ç—«å‘ç—…å‰è¡€æµ†è›‹ç™½è´¨çš„å˜åŒ–è§„å¾‹ï¼Œå‘ç°103ç§ä¸ç™«ç—«å‘ç—…é£é™©æ˜¾ç€ç›¸å…³</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzI1Njk4ODE0MQ==&amp;mid=2247533766&amp;idx=1&amp;sn=35f3d90d69dfa8c0a817ac5ded716020">HIVæ„ŸæŸ“å…ç–«å­¦æ— ååº”è€…çš„å…ç–«å¼‚è´¨æ€§åˆ†æ</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=Mzg5MDk3Mzg4OA==&amp;mid=2247498508&amp;idx=1&amp;sn=d98e432681dfea826b2b4ec962c89c87">GEOæ•°æ®ä¸ä¼šå¤„ç†ï¼Ÿä¸€ä¸ªRåŒ…å¸®ä½ æå®šå®ƒ</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzkyMTI1MTYxNA==&amp;mid=2247519906&amp;idx=1&amp;sn=8dc18472efc6d9718026bb21a6bfc77a">Molecular Cellï¼šç›‘æµ‹çº¿ç²’ä½“ç¿»è¯‘çš„å¤æ‚æ€§ä¸åŠ¨æ€</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503989&amp;idx=8&amp;sn=1c36463066c10c11f726d627dafaf192">åˆšåˆšå‘è¡¨çš„14+ç”Ÿä¿¡åˆ†æï¼Œè¯†åˆ«MMP11+æˆçº¤ç»´ç»†èƒè¿›è¡Œåˆ†æå’ŒéªŒè¯ï¼Œæœ¬æ–‡æ€è·¯æ–°é¢–ï¼Œå€¼å¾—è®¤çœŸå­¦ä¹ æ¨¡ä»¿ï¼</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247503989&amp;idx=2&amp;sn=9e5021568a2dd7bd92a02068678b49d0">ä»‹ç»ä¸¤ä¸ªç”Ÿä¿¡çƒ­ç‚¹å‘æ–‡æ€è·¯</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzI5MDQzNjY2OA==&amp;mid=2247568990&amp;idx=1&amp;sn=242deb67a33191560e9039084fa1bfbb">ä»åªèƒ½æ´»6ä¸ªæœˆï¼Œåˆ°ç”Ÿå­˜æœŸå»¶é•¿åä½™å€ï¼è¿™ç±»è‚¿ç˜¤æ­£è¿æ¥æ²»ç–—æ›™å…‰</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247507420&amp;idx=2&amp;sn=5965a20049a60eb207352e6f9d8b0286">Cellï¼šå¤šç»„ç»‡å™¨å®˜å…ç–«ç»†èƒå›¾è°±æ­ç¤ºç³»ç»Ÿå…ç–«å»ºç«‹ä¸è€å—æ–°æœºåˆ¶</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2NTE1MzU4NQ==&amp;mid=2247523446&amp;idx=1&amp;sn=e26702510c751167b49786d692f31679">åŸºäºRè¯­è¨€çš„å¾®ç”Ÿç‰©ç»„æ•°æ®æŒ–æ˜çš„æœ€ä½³æµç¨‹</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzU3OTYwNjk1NA==&amp;mid=2247523431&amp;idx=2&amp;sn=1d72492971e1d7ea67e496bb433b123f">æ–°åˆ†å­æŠ—ä½“æ–°çºªå…ƒï½œBPI 2026æˆéƒ½ç«™é¦–æ‰¹30+é¢†è¢–å°±ä½ï¼å…±ç­‘æŠ—ä½“è¯ç‰©â€œç¬¬å››æâ€å¼ºåŠ¿å´›èµ·ï¼</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248646&amp;idx=7&amp;sn=88fbc3c74e35ceb19aef9c32edba0639">67åˆ†å·¨ä½œï¼Œå¸¦ä½ ç”¨çˆ†ç«çš„ä»£è°¢é‡ç¼–ç¨‹å®ç°å¼¯é“è¶…è½¦</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248646&amp;idx=6&amp;sn=70c5687af0bc8c1bc2fe1e6f820f3e54">Nature Medicineï¼šå¾å…µæ²³é™¢å£«/é©¬é£æ•™æˆä¹³è…ºç™Œå¤§ä½œâ€”â€”å…ç–«è”åˆèŠ‚æ‹åŒ–ç–—</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248646&amp;idx=5&amp;sn=c8baeae3a009b2c14f6cf02069641ccd">ç¥ç»é€€è¡Œæ€§ç–¾ç—…æ–°çº¿ç´¢ï¼šè„‘è¡€ç®¡å†…çš®TDP-43ï¼Œè¡€è„‘å±éšœçš„â€œéšå½¢æ€æ‰‹â€ï¼Ÿ</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzUxMzk5MjY5NA==&amp;mid=2247650362&amp;idx=1&amp;sn=45171e822dff9361abcccee992de67a2">Nature èƒŒé èƒŒï¼šéª†åˆ©ç¾¤é™¢å£«å›¢é˜Ÿå®ç°ç¥ç»ç¯è·¯é‡ç¼–ç¨‹ | ä¸€ä½œä¹‹ä¸€å·²å›å›½åŠ å…¥è¥¿æ¹–å¤§å­¦</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=Mzg5NjgxNjkwOA==&amp;mid=2247503137&amp;idx=2&amp;sn=a71b68980ff704b100b13c1dd83b4532">è½¬å½•å› å­ | Nat.Genet. | åˆ©ç”¨scTF-seqè§£æè½¬å½•å› å­å‰‚é‡å¯¹ç»†èƒé‡ç¼–ç¨‹å¼‚è´¨æ€§çš„å½±å“</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&amp;mid=2247790173&amp;idx=4&amp;sn=5e1e337ff563e13bd8598d4f2fb33029">é’å²›å¤§å­¦Ã—å¤æ—¦å¤§å­¦åˆä½œCellå­åˆŠï¼šæ­ç¤ºç™«ç—«å‘ä½œç›¸å…³çš„è¡€æµ†è›‹ç™½è´¨ç»„</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&amp;mid=2247790173&amp;idx=3&amp;sn=df3241e5adbe5a2e5f949f5cd23bf2b6">è¥¿æ¹–å¤§å­¦Ã—åŒ—äº¬å¤§å­¦åˆä½œNatureå­åˆŠï¼šAIä»å¤´è®¾è®¡è›‹ç™½ï¼Œå®ç°çº¿ç²’ä½“åŸºå› ç²¾å‡†ç¼–è¾‘</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzAwMzY4MTYxNw==&amp;mid=2655821407&amp;idx=2&amp;sn=f82e06fe827063dcec1c77ecb91dd50a">ç”Ÿä¿¡æ•°æ®å¦‚ä½•æ”¯æ’‘å›½è‡ªç„¶åŸºç¡€ç ”ç©¶ï¼Ÿ</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzAwMzY4MTYxNw==&amp;mid=2655821407&amp;idx=1&amp;sn=e665d0faabe7d3376829edb50116da9d">å¦‚ä½•é€šè¿‡ç»„å­¦æ•°æ®åˆ†æï¼ŒæŒ–æ˜å›½è‡ªç„¶æ€è·¯ï¼Ÿ</a></li><li><a href="https://mp.weixin.qq.com/s?__biz=MzkxODY4NDEwMA==&amp;mid=2247490052&amp;idx=1&amp;sn=b7d0dee35ee7a128453af36e762d5bb2">èŒç¾¤ç§»æ¤åœ¨ç¥ç»ç³»ç»Ÿç–¾ç—…æ²»ç–—å’Œé¢„é˜²ä¸­çš„ä½œç”¨æœºç†</a></li></ul></div></details><details><summary><a name=æ›´å¤š-æ•°æ®å‰æ²¿></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (35æ¡)</summary><div class=details-content markdown=1><ul><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289049">GSE289049 åˆ©ç”¨åŸºå› æ¡å½¢ç å’Œå•ç»†èƒè½¬å½•ç»„å­¦è§£æé£Ÿç®¡ç™Œå‰ç—…å˜ä¸­å‰ä½“ç»†èƒçš„åŠ¨æ€å˜åŒ–</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288193">GSE288193 ç¥ç»å…ƒ GDF-15 é€’é€æ”¹å˜å¤–å‘¨ CD4+ T ç»†èƒè¡¨å‹</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282621">GSE282621 5-HT å†æ‘„å–é˜»æ–­ç ´ååŸºäºåŸºå› ç»„ç¨³å®šæ€§çš„è›‹ç™½è´¨ç¨³æ€ï¼Œé€šè¿‡é‡å¡‘ç»„è›‹ç™½è¡€æ¸…ç´ åŒ–è¯±å¯¼ç»†èƒç„¦äº¡ [RNA-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282619">GSE282619 5-HT å†æ‘„å–é˜»æ–­ç ´ååŸºäºåŸºå› ç»„ç¨³å®šæ€§çš„è›‹ç™½è´¨ç¨³æ€ï¼Œé€šè¿‡é‡å¡‘ç»„è›‹ç™½è¡€æ¸…ç´ åŒ–è¯±å¯¼ç»†èƒç„¦äº¡ [ChIP-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282082">GSE282082 ç¯çŠ¶RNA circTNK2 ä¿ƒè¿›å…ç–«é€ƒé€¸ï¼Œå¹¶å¯ä½œä¸ºä»–è«æ˜”èŠ¬è€è¯ERé˜³æ€§ä¹³è…ºç™Œçš„çº³ç±³æ²»ç–—é¶ç‚¹</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE141341">GSE141341 ä½å‰‚ã€æ€§åˆ«å’Œå¾®ç”Ÿç‰©ç»„å¯¹æ’æ²³çŒ´SIVç–«è‹—è¯±å¯¼å…ç–«å’Œä¿æŠ¤æ•ˆåŠ›çš„å½±å“</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310442">GSE310442 SARS-CoV-2 ç–«è‹—æ¥ç§åæŠ—åŸååº”æ€§ CD4 T ç»†èƒåœ¨æœ‰æˆ–æ— å†æ¬¡åˆºæ¿€çš„æƒ…å†µä¸‹è¡¨ç°å‡ºä¸åŒçš„è¡¨å‹çŠ¶æ€ [æ··åˆæ ·æœ¬]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310441">GSE310441 SARS-CoV-2 ç–«è‹—æ¥ç§åæŠ—åŸååº”æ€§ CD4 T ç»†èƒåœ¨æœ‰æˆ–æ— å†æ¬¡åˆºæ¿€çš„æƒ…å†µä¸‹è¡¨ç°å‡ºä¸åŒçš„è¡¨å‹çŠ¶æ€ [ä¸åŒæ ·æœ¬]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310364">GSE310364 IL-15 ä¸­å’Œä½œç”¨å¯å‡è½»è„‘å†…æ€¥æ€§æ…¢ç—…æ¯’ç‚ç—‡å’Œä¿¡å·ä¼ å¯¼</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE270194">GSE270194 è¡€å°æ¿å¯Œé›†è¡€æµ†å’Œè¡€å°æ¿è´«ä¹è¡€æµ†ä¸­çš„å°ç»†èƒå¤–å›Šæ³¡ä¸»è¦æ¥æºäºè¡€å°æ¿ï¼Œå¹¶èƒ½ä¿æŠ¤æ»‘è†œç»†èƒå…å—IL-1Î²è¯±å¯¼çš„ç‚ç—‡æŸä¼¤</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310491">GSE310491 å—ä½“æ¿€é…¶å¤åˆç‰©è°ƒæ§æ‹Ÿå—èŠ¥å½¢æˆå±‚æ´»æ€§</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307000">GSE307000 è‚ é“å·¨å™¬ç»†èƒè°ƒèŠ‚å¸•é‡‘æ£®ç—…ä¸­çš„è„‘çªè§¦æ ¸è›‹ç™½ç—…å˜</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302403">GSE302403 æ·¡æ°´æµ·ç»µ Ephydatia muelleri åœ¨å…‰ç…§å’Œé»‘æš—æ¡ä»¶ä¸‹å‘è‚²è¿‡ç¨‹ä¸­è—»ç±»å†…å…±ç”Ÿä½“çš„åˆ†å­å’Œç©ºé—´æ•´åˆ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE284163">GSE284163 è‡ªèº«å…ç–«æ€§è‚ç‚å°é¼ è‚è„è°ƒèŠ‚æ€§Tç»†èƒçš„æ™ºèƒ½RNAæµ‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282741">GSE282741 MeninæŠ‘åˆ¶å‰‚DS-1594bä¸Venetoclaxè”åˆä½¿ç”¨å¯ä¿ƒè¿›åˆ†åŒ–ï¼Œå¹¶åœ¨å…·æœ‰MLL1å’ŒNPM1é‡æ’çªå˜çš„æ€¥æ€§é«“ç³»ç™½è¡€ç—…ç»†èƒä¸­è¯±å¯¼ååŒè‡´æ­»ä½œç”¨</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE272082">GSE272082 å•æ ¸å¤šç»„å­¦æ­ç¤ºæ•£å‘æ€§æ—©å‘æ€§é˜¿å°”èŒ¨æµ·é»˜ç—…ä¸‰ä¸ªè„‘åŒºçš„è°ƒæ§ç¨‹åº</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285557">GSE285557 æ–°ä¸€ä»£æµ‹åºæŠ€æœ¯ä¿ƒè¿›äº†å¯¹é»‘æš—æˆ–è“å…‰å¤„ç†ä¸‹ B73 å’Œ Zmcryq çªå˜ä½“è½¬å½•ç»„çš„å®šé‡åˆ†æ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310051">GSE310051 é«˜æ¸—åº”æ¿€è¯±å¯¼ 3D æŸ“è‰²è´¨ç›¸äº’ä½œç”¨çš„å¤§è§„æ¨¡é‡ç»„ [Hi-C]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310049">GSE310049 é«˜æ¸—åº”æ¿€è¯±å¯¼ 3D æŸ“è‰²è´¨ç›¸äº’ä½œç”¨çš„å¤§è§„æ¨¡é‡ç»„ [RNA-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309786">GSE309786 PNPLA3-I148M åŸºå› å˜å¼‚é‡å¡‘è„‚è´¨ä»£è°¢ï¼Œé©±åŠ¨äººç±»è‚ç»†èƒç¨‹åºæ€§ç»†èƒæ­»äº¡</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309785">GSE309785 Tatè¡¨è¾¾å¯¹å®¿ä¸»è½¬å½•ç»„å›¾è°±çš„å½±å“ï¼Œä»¥åŠç»†èƒåœ¨æ½œä¼æœŸå„é˜¶æ®µçš„è½¬å˜</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305126">GSE305126 Lamin A/C è°ƒæ§çš„åŠèƒ±æ°¨é…¸åˆ†è§£ä»£è°¢é€šé‡é€šè¿‡è¡¨è§‚åŸºå› ç»„é‡ç¼–ç¨‹è°ƒèŠ‚å¹²ç»†èƒå‘½è¿ [ES_RNA_seq_G609G_LA_EXP2]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304993">GSE304993 Lamin A/C è°ƒæ§çš„åŠèƒ±æ°¨é…¸åˆ†è§£ä»£è°¢é€šé‡é€šè¿‡è¡¨è§‚åŸºå› ç»„é‡ç¼–ç¨‹è°ƒèŠ‚å¹²ç»†èƒå‘½è¿ [ES_RNA_seq_G609G_LA_EXP1]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304972">GSE304972 å±‚ç²˜è›‹ç™½ A/C è°ƒæ§çš„åŠèƒ±æ°¨é…¸åˆ†è§£ä»£è°¢é€šé‡é€šè¿‡è¡¨è§‚åŸºå› ç»„é‡ç¼–ç¨‹è°ƒèŠ‚å¹²ç»†èƒå‘½è¿ [ES_H3K9ac_ChIP-seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289309">GSE289309 RNA-seq åˆ†æå°é¼ è‚ºå†…çš®ç»†èƒï¼Œä»¥ç ”ç©¶ ENG ä¾èµ–æ€§å’Œ ENG éä¾èµ–æ€§ BMP9 è¯±å¯¼é¶åŸºå› ã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287935">GSE287935 CTCF è€¦åˆé•¿ç¨‹ç¯æŒ¤å‡ºå’Œæ‰©æ•£æ¥ä»‹å¯¼å¤šæ ·åŒ–çš„ Igk åº“ [ChIP-Seq]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282121">GSE282121 CT26_b2m-/- è‚¿ç˜¤æµ¸æ¶¦ NK (tuNK) çš„å•ç»†èƒæ°´å¹³åŸºå› è¡¨è¾¾è°±ï¼Œæ¥å— IL-21 æ²»ç–—æˆ– IL-21 å’Œ IL-15 è”åˆæ²»ç–—ã€‚</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281737">GSE281737 ç‹¬ç‰¹çš„DNAç”²åŸºåŒ–ç‰¹å¾å¯èƒ½æ— æ³•ç‰¹å¼‚æ€§åœ°è¡¨å¾ä¸åŒé—ä¼ å˜å¼‚ä¸­çš„BLBS</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278999">GSE278999 å±‚ç²˜è›‹ç™½ A/C è°ƒæ§çš„åŠèƒ±æ°¨é…¸åˆ†è§£ä»£è°¢é€šé‡é€šè¿‡è¡¨è§‚åŸºå› ç»„é‡ç¼–ç¨‹è°ƒèŠ‚å¹²ç»†èƒå‘½è¿ [ES_ChIP_seq_H3K9ac_H3K27ac_LA]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278998">GSE278998 Lamin A/C è°ƒæ§çš„åŠèƒ±æ°¨é…¸åˆ†è§£ä»£è°¢é€šé‡é€šè¿‡è¡¨è§‚åŸºå› ç»„é‡ç¼–ç¨‹è°ƒèŠ‚å¹²ç»†èƒå‘½è¿ [ES_ChIP_seq_H3K9me3_LA]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE249274">GSE249274 å°¼éæ—é€šè¿‡è°ƒèŠ‚å¤šç§ä¿¡å·é€šè·¯æ”¹å–„é«˜è¡€å‹å¼•èµ·çš„å¿ƒè„é‡å¡‘â€”â€”å¿ƒè„</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE248534">GSE248534 å±‚ç²˜è›‹ç™½A/Cè°ƒæ§çš„åŠèƒ±æ°¨é…¸åˆ†è§£ä»£è°¢é€šé‡é€šè¿‡è¡¨è§‚åŸºå› ç»„é‡ç¼–ç¨‹è°ƒèŠ‚å¹²ç»†èƒå‘½è¿</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE248533">GSE248533 Lamin A/C è°ƒæ§çš„åŠèƒ±æ°¨é…¸åˆ†è§£ä»£è°¢é€šé‡é€šè¿‡è¡¨è§‚åŸºå› ç»„é‡ç¼–ç¨‹è°ƒèŠ‚å¹²ç»†èƒå‘½è¿ [04scRNA_seq_D10]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE248530">GSE248530 Lamin A/C è°ƒæ§çš„åŠèƒ±æ°¨é…¸åˆ†è§£ä»£è°¢é€šé‡é€šè¿‡è¡¨è§‚åŸºå› ç»„é‡ç¼–ç¨‹è°ƒèŠ‚å¹²ç»†èƒå‘½è¿ [bulkPolyA_RNA_seq_LA_ES]</a></li><li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE248421">GSE248421 USP51-GRP78è½´é€šè¿‡è°ƒèŠ‚ABCB1çš„æ´»æ€§ä¿ƒè¿›ä¸‰é˜´æ€§ä¹³è…ºç™Œç»†èƒå¯¹é˜¿éœ‰ç´ çš„è€è¯æ€§ã€‚</a></li></ul></div></details><hr><p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-11-20 21:33</em><br><em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p></div><footer class=post__footer><div class="post__tags tags clearfix"><svg class="tags__badge icon icon-tag" width="16" height="16" viewBox="0 0 32 32"><path d="M4 0h8s2 0 4 2l15 15s2 2 0 4L21 31s-2 2-4 0L2 16s-2-2-2-4V3s0-3 4-3m3 10a3 3 0 000-6 3 3 0 000 6"/></svg><ul class=tags__list><li class=tags__item><a class="tags__link btn" href=../../../tags/research/ rel=tag>Research</a></li><li class=tags__item><a class="tags__link btn" href=../../../tags/daily/ rel=tag>Daily</a></li><li class=tags__item><a class="tags__link btn" href=../../../tags/week472025/ rel=tag>Week472025</a></li></ul></div></footer></article></main><div class="authorbox clearfix"><div class=authorbox__header><span class=authorbox__name>About Bloger</span></div></div><nav class="pager flex"><div class="pager__item pager__item--prev"><a class=pager__link href=../../../posts/dailyreports/2025-11-20/ rel=prev><span class=pager__subtitle>Â«&#8201;Previous</span><p class=pager__title>ç§‘ç ”æ—¥æŠ¥ 2025-11-20</p></a></div><div class="pager__item pager__item--next"><a class=pager__link href=../../../posts/dailyreports/2025-11-22/ rel=next><span class=pager__subtitle>Next&#8201;Â»</span><p class=pager__title>ç§‘ç ”æ—¥æŠ¥ 2025-11-22</p></a></div></nav><section class=comments><div id=disqus_thread></div><script>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//kkitown.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></section></div><aside class=sidebar><div class="widget-search widget"><form class=widget-search__form role=search method=get action=https://google.com/search><input class=widget-search__field type=search placeholder=Searchâ€¦ name=q aria-label=Searchâ€¦>
<input class=widget-search__submit type=submit value=Search>
<input type=hidden name=sitesearch value=https://ixxmu.github.io/></form></div><div class="widget-recent widget"><h4 class=widget__title>Recent Posts</h4><div class=widget__content><ul class=widget__list><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-26/>ç§‘ç ”æ—¥æŠ¥ 2026-02-26</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-25/>ç§‘ç ”æ—¥æŠ¥ 2026-02-25</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-24/>ç§‘ç ”æ—¥æŠ¥ 2026-02-24</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-23/>ç§‘ç ”æ—¥æŠ¥ 2026-02-23</a></li><li class=widget__item><a class=widget__link href=../../../posts/dailyreports/2026-02-22/>ç§‘ç ”æ—¥æŠ¥ 2026-02-22</a></li></ul></div></div><div class="widget-categories widget"><h4 class=widget__title>Categories</h4><div class=widget__content><ul class=widget__list><li class=widget__item><a class=widget__link href=../../../categories/dailyreport/>DailyReport</a></li><li class=widget__item><a class=widget__link href=../../../categories/learnr/>LearnR</a></li></ul></div></div><div class="widget-taglist widget"><h4 class=widget__title>Tags</h4><div class=widget__content><a class="widget-taglist__link widget__link btn" href=../../../tags/daily/ title=Daily>Daily (119)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/research/ title=Research>Research (119)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week022026/ title=Week022026>Week022026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week032026/ title=Week032026>Week032026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week042026/ title=Week042026>Week042026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week052026/ title=Week052026>Week052026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week062026/ title=Week062026>Week062026 (6)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week072026/ title=Week072026>Week072026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week082026/ title=Week082026>Week082026 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week452025/ title=Week452025>Week452025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week462025/ title=Week462025>Week462025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week472025/ title=Week472025>Week472025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week482025/ title=Week482025>Week482025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week492025/ title=Week492025>Week492025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week502025/ title=Week502025>Week502025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week512025/ title=Week512025>Week512025 (7)</a>
<a class="widget-taglist__link widget__link btn" href=../../../tags/week522025/ title=Week522025>Week522025 (7)</a></div><a href=../../../tags/></a></div><div class="widget-social widget"><h4 class="widget-social__title widget__title">Social</h4><div class="widget-social__content widget__content"><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Facebook rel="noopener noreferrer" href=https://facebook.com/username target=_blank><svg class="widget-social__link-icon icon icon-facebook" width="24" height="24" viewBox="0 0 352 352"><path d="m0 32v288c0 17.5 14.5 32 32 32h288c17.5.0 32-14.5 32-32V32c0-17.5-14.5-32-32-32H32C14.5.0.0 14.5.0 32zm320 0v288h-83V212h41.5l6-48H237v-31c0-14 3.5-23.5 23.5-23.5h26V66c-4.4-.6-19.8-1.5-37.5-1.5-36.9.0-62 22.2-62 63.5v36h-42v48h42v108H32V32z"/></svg>
<span>Facebook</span></a></div><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Twitter rel="noopener noreferrer" href=https://twitter.com/username target=_blank><svg class="widget-social__link-icon icon icon-twitter" width="24" height="24" viewBox="0 0 384 312"><path d="m384 36.9c-14.1 6.3-29.3 10.5-45.2 12.4 16.3-9.7 28.8-25.2 34.6-43.6-15.2 9-32.1 15.6-50 19.1-14.4-15.2-34.9-24.8-57.5-24.8-43.5.0-78.8 35.3-78.8 78.8.0 6.2.7 12.2 2 17.9-65.5-3.3-123.5-34.6-162.4-82.3C20 26 16.1 39.6 16.1 54c0 27.3 13.9 51.4 35 65.6-12.9-.4-25.1-4-35.7-9.9v1c0 38.2 27.2 70 63.2 77.2-6.6 1.8-13.6 2.8-20.8 2.8-5.1.0-10-.5-14.8-1.4 10 31.3 39.1 54.1 73.6 54.7-27 21.1-60.9 33.7-97.8 33.7-6.4.0-12.6-.4-18.8-1.1C34.9 299 76.3 312 120.8 312c144.9.0 224.1-120 224.1-224.1.0-3.4-.1-6.8-.2-10.2 15.4-11.1 28.7-25 39.3-40.8z"/></svg>
<span>Twitter</span></a></div><div class="widget-social__item widget__item"><a class="widget-social__link widget__link btn" title=Instagram rel="noopener noreferrer" href=https://www.instagram.com/username target=_blank><svg class="widget-social__link-icon icon icon-instagram" width="24" height="24" viewBox="0 0 256 256"><circle cx="193" cy="59" r="15"/><path fill-rule="evenodd" d="M101 0h54c41 0 58.4 3.9 74.5 17C256.2 37.5 256 74.8 256 97.7v60c0 26.7.0 60.4-26.5 81.4-16 13.4-33.5 16.9-74.5 16.9h-54c-41 0-57.5-3.5-74.5-16.9C1 218.9.5 186.3.1 160.5L0 155V97.7c0-23-.2-60.2 26.5-80.7C45 2 60 0 101 0zm4.9 23h44.3c45.8.0 58.3 3.5 70.3 17.5 11.8 13.2 12 30.1 12.5 62.9V156c.2 20.8.3 45.8-12.5 59.5-12 14-24.5 17.5-70.3 17.5h-44.3c-45.9.0-57.3-3.5-70.4-17.5-12.2-13-12.3-36.5-12.4-56.7v-55.6c.4-32.6.7-49.6 12.4-62.7C48 26.5 60 23 105.9 23zm19.6 144.5a42 42 0 100-84 42 42 0 000 84zm0 22.5a64.5 64.5.0 100-129 64.5 64.5.0 000 129z"/></svg>
<span>Instagram</span></a></div></div></div></aside></div><footer class=footer><div class="container footer__container flex"><div class=footer__copyright>&copy; 2026 ç”Ÿä¿¡æ™®æ‹‰æ–¯.
<span class=footer__copyright-credits>Generated with <a href=https://gohugo.io/ rel="nofollow noopener" target=_blank>Hugo</a> and <a href=https://github.com/Vimux/Mainroad/ rel="nofollow noopener" target=_blank>Mainroad</a> theme.</span></div></div></footer></div><script async defer src=../../../js/menu.js></script><script src=../../../js/custom.js></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.6/MathJax.js?config=TeX-AMS-MML_HTMLorMML" async></script></body></html>